155 results on '"Marie Hu"'
Search Results
2. Poor Survival Outcomes of Checkpoint Inhibitors for B-Cell Lymphomas Relapsing after or Refractory to CAR T-Cell Therapy: A Real-World Cohort from 15 U.S. Academic Institutions
- Author
-
Ajay Major, Jovian Yu, Navika D. Shukla, Rachel Treitman, Manali K. Kamdar, Bradley M. Haverkos, James Godfrey, Melissa A. Babcook, Timothy J. Voorhees, Sophie G Carlson, Daria Gaut, Caspian Oliai, Jason T. Romancik, Allison Winter, Brian T. Hill, Radhika Bansal, Jose C. Villasboas, Imran A. Nizamuddin, Reem Karmali, Lindsey A. Fitzgerald, Deborah M. Stephens, Priyanka A. Pophali, Asaad Trabolsi, Jonathan H. Schatz, Marie Hu, Veronika Bachanova, Michael J Slade, Nathan Singh, Nausheen Ahmed, Joseph P. McGuirk, Michael R. Bishop, Peter A. Riedell, and Justin Kline
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
- Full Text
- View/download PDF
3. Long-term adaptation of lymphoma cell lines to hypoxia is mediated by diverse molecular mechanisms that are targetable with specific inhibitors
- Author
-
Lenka Daumova, Dmitry Manakov, Jiri Petrak, Dana Sovilj, Matej Behounek, Ladislav Andera, Ondrej Vit, Olga Souckova, Ondrej Havranek, Alex Dolnikova, Nicol Renesova, Liliana Tuskova, Lucie Winkowska, Nardjas Bettazova, Kristyna Kupcova, Marie Hubalek Kalbacova, Miriama Sikorova, Marek Trneny, and Pavel Klener
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 ,Cytology ,QH573-671 - Abstract
Abstract A large body of evidence suggests that hypoxia drives aggressive molecular features of malignant cells irrespective of cancer type. Non-Hodgkin lymphomas (NHL) are the most common hematologic malignancies characterized by frequent involvement of diverse hypoxic microenvironments. We studied the impact of long-term deep hypoxia (1% O2) on the biology of lymphoma cells. Only 2 out of 6 tested cell lines (Ramos, and HBL2) survived ≥ 4 weeks under hypoxia. The hypoxia-adapted (HA)b Ramos and HBL2 cells had a decreased proliferation rate accompanied by significant suppression of both oxidative phosphorylation and glycolytic pathways. Transcriptome and proteome analyses revealed marked downregulation of genes and proteins of the mitochondrial respiration complexes I and IV, and mitochondrial ribosomal proteins. Despite the observed suppression of glycolysis, the proteome analysis of both HA cell lines showed upregulation of several proteins involved in the regulation of glucose utilization including the active catalytic component of prolyl-4-hydroxylase P4HA1, an important druggable oncogene. HA cell lines demonstrated increased transcription of key regulators of auto-/mitophagy, e.g., neuritin, BCL2 interacting protein 3 (BNIP3), BNIP3-like protein, and BNIP3 pseudogene. Adaptation to hypoxia was further associated with deregulation of apoptosis, namely upregulation of BCL2L1/BCL-XL, overexpression of BCL2L11/BIM, increased binding of BIM to BCL-XL, and significantly increased sensitivity of both HA cell lines to A1155463, a BCL-XL inhibitor. Finally, in both HA cell lines AKT kinase was hyperphosphorylated and the cells showed increased sensitivity to copanlisib, a pan-PI3K inhibitor. In conclusion, our data report on several shared mechanisms of lymphoma cell adaptation to long-term hypoxia including: 1. Upregulation of proteins responsible for glucose utilization, 2. Degradation of mitochondrial proteins for potential mitochondrial recycling (by mitophagy), and 3. Increased dependence on BCL-XL and PI3K-AKT signaling for survival. In translation, inhibition of glycolysis, BCL-XL, or PI3K-AKT cascade may result in targeted elimination of HA lymphoma cells.
- Published
- 2025
- Full Text
- View/download PDF
4. Homologous recombination deficiency (HRD) testing landscape: clinical applications and technical validation for routine diagnostics
- Author
-
Andréa Witz, Julie Dardare, Margaux Betz, Cassandra Michel, Marie Husson, Pauline Gilson, Jean-Louis Merlin, and Alexandre Harlé
- Subjects
Homologous recombination deficiency ,HRD status ,PARP inhibitors ,Genomic scars analysis ,BRCA mutations testing ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Abstract The use of poly(ADP-ribose) polymerase inhibitors (PARPi) revolutionized the treatment of BRCA-mutated cancers. Identifying patients exhibiting homologous recombination deficiency (HRD) has been proved useful to predict PARPi efficacy. However, obtaining HRD status remains an arduous task due to its evolution over the time. This causes HRD status to become obsolete when obtained from genomic scars, rendering PARPi ineffective for these patients. Only two HRD tests are currently FDA-approved, both based on genomic scars detection and BRCA mutations testing. Nevertheless, new technologies for obtaining an increasingly reliable HRD status continue to evolve. Application of these tests in clinical practice is an additional challenge due to the need for lower costs and shorter time to results delay. In this review, we describe the currently available methods for HRD testing, including the methodologies and corresponding tests for assessing HRD status, and discuss the clinical routine application of these tests and their technical validation.
- Published
- 2025
- Full Text
- View/download PDF
5. High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study
- Author
-
Adam Stephen Zayac, Daniel J. Landsburg, Mitchell E. Hughes, Allison M. Bock, Grzegorz S. Nowakowski, Emily C. Ayers, Mark Ryan Girton, Marie Hu, Amy K. Beckman, Shaoying Li, L. Jeffrey Medeiros, Julie E Chang, Adam Stepanovic, Habibe Kurt, Jose Sandoval-Sus, Mohammad Ali Ansari-Lari, Shalin K. Kothari, Anna Kress, Mina L Xu, Pallawi Torka, Suchitra Sundaram, Stephen D Smith, Kikkeri N Naresh, Yasmin H. Karimi, Narendranath Epperla, David A Bond, Umar Farooq, Mahak Saad, Andrew M Evens, Karan Pandya, Seema G. Naik, Manali Kamdar, Bradley M Haverkos, Reem Karmali, Timothy S Oh, Julie M Vose, Heather R Nutsch, Paul G. Rubinstein, Amina Chaudhry, and Adam J Olszewski
- Subjects
Hematology - Abstract
In this multi-institutional retrospective study, we examined characteristics and outcomes of 160 patients with high-grade B-cell lymphoma, not otherwise specified (HGBL-NOS). This rare lymphoma category is defined by high-grade morphologic features, most commonly Burkitt-like, and lack of MYC rearrangements with BCL2 and/or BCL6 rearrangements (so-called double-hit). Our results show that HGBL-NOS tumors are heterogeneous: 83% had a germinal center B-cell immunophenotype, 37% a dual expressor immunophenotype (MYC and BCL2 expression), 28% (single-hit) MYC rearrangement, 13% BCL2 rearrangement, and 11% BCL6 rearrangement. Most patients presented with stage 4 disease, a high serum lactate dehydrogenase, and other high-risk clinical factors. Most frequent first-line regimens included DA-EPOCH-R (43%), R-CHOP (33%), or other intensive chemotherapy programs (11%). We found no significant differences in the rates of complete response (CR, P=0.32), progression-free (PFS, P=0.82), or overall survival (OS, P=0.60) between these chemotherapy regimens. CR was attained by 69% of patients. PFS at 2 years was 55.2% (95%CI, 46.9-62.7), and OS was 68.1% (95%CI, 59.7-75.0). In a multivariable model, the main prognostic factors for PFS and OS were poor performance status, lactate dehydrogenase >3x upper limit of normal, and a dual expressor immunophenotype. Age >60 years or presence of MYC rearrangement were not prognostic, but patients with TP53 alterations had a dismal PFS (13% at 2 years). Presence of MYC rearrangement was not predictive of better PFS in patients treated with DA-EPOCH-R versus R-CHOP. Improvements in the diagnostic criteria and therapeutic approaches beyond dose-intense chemotherapy are needed to overcome the unfavorable prognosis of patients with HGBL-NOS.
- Published
- 2023
- Full Text
- View/download PDF
6. Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: Outcomes from 15 U.S. institutions
- Author
-
Ajay Major, Jovian Yu, Navika Shukla, Yan Che, Theodore G Karrison, Rachel Treitman, Manali Kamdar, Bradley M Haverkos, James Godfrey, Melissa A Babcook, Timothy J Voorhees, Sophie Gabrielle Carlson, Daria Gaut, Caspian Oliai, Jason T. Romancik, Allison M Winter, Brian T. Hill, Radhika Bansal, Jose Caetano Villasboas, Imran A. Nizamuddin, Reem Karmali, Lindsey A. Fitzgerald, Deborah M. Stephens, Priyanka A Pophali, Asaad Trabolsi, Jonathan H Schatz, Marie Hu, Veronika Bachanova, Michael Slade, Nathan Singh, Nausheen Ahmed, Joseph P McGuirk, Michael R. Bishop, Peter A. Riedell, and Justin Kline
- Subjects
Hematology - Abstract
Checkpoint inhibitor (CPI) therapy with anti-PD-1 antibodies has been associated with mixed outcomes in small cohorts of aggressive B-cell lymphoma patients following CAR T-cell therapy failure. To more definitively define CPI therapy efficacy in this population, we retrospectively evaluated clinical outcomes in a large cohort of 96 patients with aggressive B-cell lymphomas receiving CPI therapy after CAR-T failure across 15 U.S. academic centers. Most patients (53%) had DLBCL, were treated with axicabtagene ciloleucel (53%), relapsed early (≤180 days) after CAR-T (83%), and received pembrolizumab (49%) or nivolumab (43%). CPI therapy was associated with an overall response rate of 19% and a complete response rate of 10%. Median duration of response was 221 days. Median progression-free survival (PFS) and overall survival (OS) were 54 and 159 days, respectively. Outcomes to CPI therapy were significantly improved in patients with primary mediastinal B-cell lymphoma. PFS (128 versus 51 days) and OS (387 versus 131 days) were significantly longer in patients with late (>180 days) versus early (≤180 days) relapse after CAR-T. Grade ≥3 adverse events occurred in 19% of CPI-treated patients. Most patients (83%) died, commonly due to progressive disease. Only 5% had durable responses to CPI therapy. In the largest cohort of aggressive B-cell lymphoma patients treated with CPI therapy after CAR-T relapse, our results reveal poor outcomes, particularly among those relapsing early after CAR-T. In conclusion, CPI therapy is not an effective salvage strategy for most patients after CAR-T, where alternative approaches are needed to improve post-CAR-T outcomes.
- Published
- 2023
- Full Text
- View/download PDF
7. Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel Recipients for B Cell Non-Hodgkin Lymphoma
- Author
-
Nausheen Ahmed, William Wesson, Muhammad Umair Mushtaq, David L. Porter, Sunita D. Nasta, Jamie Brower, Veronika Bachanova, Marie Hu, Loretta J. Nastoupil, Olalekan O. Oluwole, Vivek G. Patel, Caspian Oliai, Peter A. Riedell, Michael R. Bishop, Gunjan L. Shah, Miguel-Angel Perales, Levanto Schachter, Richard T. Maziarz, and Joseph P. McGuirk
- Subjects
Transplantation ,Molecular Medicine ,Immunology and Allergy ,Cell Biology ,Hematology - Published
- 2023
- Full Text
- View/download PDF
8. High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Central Nervous System (CNS) Involvement, Prophylaxis, and Recurrence Risk in a Multi-Institutional Series
- Author
-
Narendranath Epperla, Adam Zayac, Daniel J. Landsburg, Mitchell Hughes, Allison M. Bock, Grzegorz S. Nowakowski, Emily C. Ayers, Mark Girton, Marie Hu, Amy Beckman, Shaoying Li, L. Jeffrey Medeiros, Julie E. Chang, Adam Stepanovic, Habibe Kurt, Jose Sandoval-Sus, M. Ali Ansari-Lari, Shalin K. Kothari, Anna Kress, Mina L Xu, Pallawi Torka, Suchitra Sundaram, Stephen D Smith, Kikkeri N Naresh, Yasmin Karimi, David A. Bond, Umar Farooq, Mahak Saad, Andrew Matthew Evens, Karan Pandya, Seema G Naik, Manali Kamdar, Bradley M. Haverkos, Reem Karmali, Timothy S Oh, Julie M. Vose, Heather Nutsch, Paul Rubinstein, Amina Chaudhry, and Adam J. Olszewski
- Subjects
Immunology ,Cell Biology ,Hematology ,Biochemistry - Published
- 2022
- Full Text
- View/download PDF
9. Langerhans cell histiocytosis with lung involvement in isolation and multisystem disease: Staging, natural history, and comparative survival
- Author
-
Karen L. Rech, Matthew J. Koster, Antonious Z. Hazim, Aishwarya Ravindran, Jay H. Ryu, Jithma P. Abeykoon, Marie Hu, Christian W. Cox, Gaurav Goyal, Robert Vassallo, W. Oliver Tobin, Ronald S. Go, N. Nora Bennani, Mithun Vinod Shah, Jason R. Young, Gordon Ruan, and Caleb Scheckel
- Subjects
Adult ,Male ,medicine.medical_specialty ,Radiography ,Disease ,Gastroenterology ,Young Adult ,Langerhans cell histiocytosis ,Internal medicine ,Humans ,Medicine ,Lung ,Aged ,Retrospective Studies ,Fluorodeoxyglucose ,business.industry ,Retrospective cohort study ,Hematology ,Middle Aged ,Prognosis ,medicine.disease ,Survival Analysis ,Confidence interval ,Multisystem disease ,Natural history ,Histiocytosis, Langerhans-Cell ,Female ,business ,medicine.drug - Abstract
Langerhans cell histiocytosis (LCH) is a histiocytic neoplasm that can involve the lungs as single system (LCH-SSL) or multisystem disease (LCH-MSL). The role of full-body radiographic staging to determine whether patients have LCH-SSL or LCH-MSL is unclear. Long-term outcomes of LCH-SSL versus LCH-MSL and multisystem without lung involvement (LCH-MSNL) are unknown. A retrospective study of adult LCH patients seen at our center from January 2000 to 2020 was performed. In Part 1, we addressed utility of whole-body staging imaging among those presenting with isolated pulmonary signs or symptoms. Staging was defined as fluorodeoxyglucose positron emission tomography-computed tomography (CT) or whole-body CT obtained within 3 months of diagnosis. In Part 2, we examined the frequency of developing extra-pulmonary disease over time and mortality in patients with LCH-SSL. In Part 3, we compared the overall survival of LCH-SSL, LCH-MSL, and LCH-MSNL. Part 1: 240 patients with LCH were identified. A total of 112 (47%) had pulmonary signs or symptoms at presentation. Thirty-four (30%) underwent radiographic staging and only one showed evidence of extra-pulmonary disease. Part 2: 108 (45%) were LCH-SSL. Median follow-up duration of 4.5 years (95% confidence interval [CI]: 2.9-6.0). None developed extra-pulmonary disease. Part 3: 5-year survival: 94% (95% CI: 84%-98%) for LCH-SSL, 78% (95% CI: 59%-90%) for LCH-MSL, and 75% (95% CI: 53%-89%) for LCH-MSNL. LCH patients presenting with isolated pulmonary signs or symptoms rarely have extra-pulmonary involvement at the time of diagnosis and generally do not develop extra-pulmonary progression. LCH-SSL has the best overall survival, while LCH-MSL and LCH-MSNL have similar clinical outcomes.
- Published
- 2021
- Full Text
- View/download PDF
10. Chronicity of Immune Checkpoint Inhibitor–Associated Inflammatory Arthritis After Immunotherapy Discontinuation: Results From the Canadian Research Group of Rheumatology in Immuno‐Oncology Database
- Author
-
Alexandra Ladouceur, Shahin Jamal, Alexandra Saltman, Megan Himmel, Marie Hudson, Janet Pope, Sabrina Hoa, Janet Roberts, Inés Colmegna, Lourdes Gonzalez Arreola, Tatiana Nevskaya, Ammana Karmali, David Moon, Emma Schmidt, Nader Toban, Lindsay Cho, Thomas Barnetche, and Carrie Ye
- Subjects
Diseases of the musculoskeletal system ,RC925-935 - Abstract
Objective Immune checkpoint inhibitors (ICIs) improve overall survival (OS) and progression‐free survival (PFS) in many types of malignancies but can result in off‐target immune‐related adverse events including inflammatory arthritis (ICI‐associated inflammatory arthritis [ICI‐IA]), which can persist even after ICI cessation. We aimed to examine the proportion of patients with ICI‐IA who develop chronic ICI‐IA and describe characteristics and outcomes associated with chronic ICI‐IA. Methods We identified patients from the Canadian Research Group of Rheumatology in Immuno‐Oncology retrospective cohort who developed de novo ICI‐IA with at least three months of follow‐up after ICI cessation. Chronic ICI‐IA was defined as symptoms or ongoing immunosuppression lasting beyond three months after ICI discontinuation. Acute ICI‐IA was defined as resolution of ICI‐IA symptoms and discontinuation of immunosuppression within three months of ICI discontinuation. OS and PFS were assessed with Kaplan–Meier curves. Landmark multivariable Cox proportional hazard models for OS and PFS were conducted. Results The study cohort included 119 patients. A total of 15 patients (13%) had acute ICI‐IA, whereas 104 (87%) had chronic ICI‐IA. Patients with chronic ICI‐IA were more likely to be White and to have polyarthritis at presentation. After adjusting for age, sex, tumor type, stage of cancer, ICI‐IA treatment, and time from ICI initiation to ICI‐IA onset, patients with chronic ICI‐IA had greater PFS from ICI initiation (adjusted hazard ratio 0.27, 95% confidence interval 0.08–0.98; P = 0.046). Adjusted hazard ratio for OS was similar between those with acute versus chronic ICI‐IA. Conclusion ICI‐IA frequently persists after ICI discontinuation. Chronic ICI‐IA is associated with improved PFS, but not OS, as compared to acute ICI‐IA.
- Published
- 2025
- Full Text
- View/download PDF
11. Barriers to Commercial CAR-T Referral and Utilization for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Single-Institution Analysis
- Author
-
Marie Hu, Vidhyalakshmi Ramesh, Nuttavut Sumransub, Alma Habib, Joseph E. Maakaron, and Veronika Bachanova
- Subjects
Transplantation ,Molecular Medicine ,Immunology and Allergy ,Cell Biology ,Hematology - Published
- 2023
- Full Text
- View/download PDF
12. DDB2 expression lights the way for precision radiotherapy response in PDAC cells, with or without olaparib
- Author
-
Julie Dardare, Andréa Witz, Margaux Betz, Aurélie François, Laureline Lamy, Marie Husson, Jessica Demange, Marie Rouyer, Aurélien Lambert, Jean-Louis Merlin, Pauline Gilson, and Alexandre Harlé
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 ,Cytology ,QH573-671 - Abstract
Abstract Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers. Therapeutic options for PDAC are primarily restricted to surgery in the early stages of the disease or chemotherapy in advanced disease. Only a subset of patients with germline defects in BRCA1/2 genes can potentially benefit from personalized therapy, with the PARP inhibitor olaparib serving as a maintenance treatment for metastatic disease. Although the role of radiotherapy in PDAC remains controversial, the use of radiosensitizers offers hope for improving cancer management. Previously, we have shown that damage-specific DNA binding protein 2 (DDB2) is a potential prognostic and predictive biomarker for chemotherapy response in PDAC. In this study, we investigated the function of DDB2 in radiotherapy response, with and without radiosensitization by olaparib in PDAC cells. Our findings demonstrated DDB2 resistance to radiation effects, thereby improving cell survival and enhancing the repair of ionizing radiation-induced DNA double-strand breaks. We observed that DDB2 expression enhances the cell cycle arrest in the G2 phase by phosphorylating Chk1 and Chk2 cell cycle checkpoints. Additionally, we identified a novel link between DDB2 and PARP1 in the context of radiotherapy, which enhances the expression and activity of PARP1. Our findings highlight the potential of low-DDB2 expression to potentiate the radiosensitization effect of olaparib in PDAC cells. Collectively, this study provides novel insights into the impacts of DDB2 in the radiotherapy response in PDAC, enabling its employment as a potential biomarker to predict resistance to radiation. Furthermore, DDB2 represents a significant step forward in precision radiotherapy by widening the scope of patients who can be benefiting from olaparib as a radiosensitizer. Hence, this research has the potential to enrich the limited use of radiotherapy in the care of patients with PDAC.
- Published
- 2024
- Full Text
- View/download PDF
13. As-deposited and dewetted Cu layers on plasma treated glass: Adhesion study and its effect on biological response
- Author
-
Alena Reznickova, Veronika Lacmanova, Marie Hubalek Kalbacova, Petr Hausild, Jiri Nohava, Zdenka Kolska, Anna Kutova, and Petr Slepicka
- Subjects
Glass ,Copper ,Sputtering ,Annealing ,Adhesion ,Cytotoxicity ,Materials of engineering and construction. Mechanics of materials ,TA401-492 ,Industrial electrochemistry ,TP250-261 - Abstract
Improving the adhesion of nanosized copper films to a glass substrate is vital for their application in electronics and medicine, as it enhances their overall reliability. For this purpose, we employed Ar plasma etching (240 s) and magnetron sputtering to create copper layers on a glass substrate. Furthermore, we investigated the effect of subsequent solid state dewetting (at 300 °C) of Cu nanolayers on the interface stability. Increasing the sputtering time resulted in elevated copper concentration, UV-Vis absorption, conductivity, and surface roughness. The as-deposited and dewetted samples exhibited very good wettability with water contact angles below 60°. Importantly, plasma treatment improved the adhesion of the Cu layers to the glass. Subsequent dewetting accelerated surface diffusion and the oxidation of Cu atoms, causing structural and morphological changes. The presence of CuO after dewetting caused loss of the surface plasmon resonance (SPR) band in the UV-Vis spectrum and a decrease in sample conductivity due to the transformation of the copper layer from a metal to an oxide. Biological testing revealed a more pronounced bactericidal effect for the as-deposited Cu layer against E. coli and S. epidermidis on contrary to dewetted samples. The similar cytotoxic trend was observed for human dermal fibroblasts and hepatocytes. Nonetheless, biological testing confirmed better cell adhesion on dewetted Cu layers compared to the as-deposited ones. Therefore, our copper nanostructured samples could find application as antibacterial coatings of biomedical devices.
- Published
- 2024
- Full Text
- View/download PDF
14. A Bayesian adaptive feasibility design for rare diseases
- Author
-
Maureen M. Churipuy, Shirin Golchi, Marie Hudson, and Sabrina Hoa
- Subjects
Clinical trial ,Bayesian ,Feasibility ,Rare disease ,Pilot trial ,Recruitment ,Medicine (General) ,R5-920 - Abstract
It is important for researchers to carefully assess the feasibility of a clinical trial prior to the launch of the study. One feasibility aspect that needs to be considered includes whether investigators can expect to successfully achieve the sample size needed for their trial. In this manuscript, we present a Bayesian design in which data collected during a pilot study is used to predict the feasibility of a planned phase III trial. Specifically, we outline a model that predicts a target sample size obtained from the Gamma-Poisson distribution. In a simulation study, we showcase the utility of the proposed design by applying it to a phase III trial designed to assess the efficacy of mycophenolate mofetil in individuals with mild systemic sclerosis. We demonstrate that the predictive nature of the proposed design is particularly useful for rare disease clinical trials and has the potential to greatly increase their efficiency.
- Published
- 2024
- Full Text
- View/download PDF
15. Sarcopenia Predicts Inferior Progression Free Survival in Lymphoma Patients Treated with Autologous Hematopoietic Stem Cell Transplantation
- Author
-
Nuttavut Sumransub, Qing Cao, Mark Juckett, Brian C. Betts, Shernan Holtan, Najla El Jurdi, Marie Hu, Veronika Bachanova, Mukta Arora, and Joseph E. Maakaron
- Subjects
Transplantation ,Molecular Medicine ,Immunology and Allergy ,Cell Biology ,Hematology - Published
- 2022
- Full Text
- View/download PDF
16. Chimeric antigen receptor T cell therapy for cancer: clinical applications and practical considerations
- Author
-
Joseph E Maakaron, Marie Hu, and Najla El Jurdi
- Subjects
General Medicine - Abstract
Chimeric antigen receptor T cells have revolutionized the treatment of hematological malignancies during the past five years, boasting impressive response rates and durable remissions for patients who previously had no viable options. In this review, we provide a brief historical overview of their development. We focus on the practical aspects of a patient’s journey through this treatment and the unique toxicities and current best practices to manage those. We then discuss the key registration trials that have led to approvals for the treatment of relapsed/refractory acute lymphoblastic leukemia (ALL), diffuse large B cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma (MCL), and multiple myeloma. Finally, we consider the future development and research directions of this cutting edge therapy.
- Published
- 2022
- Full Text
- View/download PDF
17. Broken Lyres: Epic, Performance, and History in Mehdi Akhavān Sāles’ 'Ākhar-e Shāhnāmeh'
- Author
-
Marie Huber
- Subjects
persian poetry ,epic poetry ,ferdowsi ,modern iran ,storytelling ,Discourse analysis ,P302-302.87 ,Literature (General) ,PN1-6790 - Abstract
In “Ākhar-e Shāhnāmeh” by Mehdi Akhavān Sāles (1929-1990), one of the foremost representatives of “New Poetry” in Iran, a fictive orality is staged: The poem becomes decipherable only to a reader attuned to the tradition of epic storytelling. This paper examines the relationship between language, perception, self, time, and world created through the fiction of storytelling. Drawing on theories of perception, narrative time, and epic performance, our discussion touches upon the nature of “I” and “we”, the shifting narrative grounds and identities enacted by the narration, the imbrication of past and present in the figure of the storyteller, and the memory spaces that are created both in and through the text. The imaginary speech act of the storyteller casts the reader as audience, while at the same time, the epic past is overlayed by a tumble-down present. Language itself becomes incommensurable with what it describes. Rather than a nostalgic invocation of a lost age of epic heroes, as has often been claimed, ĀKHAR-E SHĀHNĀMEH emerges as the profoundly modern diagnosis of a split consciousness that affects the individual in a society that can no longer return to epic naïveté.
- Published
- 2024
- Full Text
- View/download PDF
18. Single‐agent cladribine as an effective front‐line therapy for adults with Langerhans cell histiocytosis
- Author
-
Karen L. Rech, Jason R. Young, Ronald S Go, Mithun Vinod Shah, Caroline J. Davidge-Pitts, Robert Vassallo, Animesh Pardanani, Aishwarya Ravindran, C. Christopher Hook, Matthew J. Koster, N. Nora Bennani, Jithma P. Abeykoon, W. Oliver Tobin, Gaurav Goyal, Jay H. Ryu, Marie Hu, Timothy G. Call, and David J. Inwards
- Subjects
Adult ,Male ,Proto-Oncogene Proteins B-raf ,MAP Kinase Signaling System ,Mutation, Missense ,Kaplan-Meier Estimate ,Article ,Young Adult ,Langerhans cell histiocytosis ,Positron Emission Tomography Computed Tomography ,Humans ,Point Mutation ,Medicine ,Single agent ,Cladribine ,Aged ,Retrospective Studies ,business.industry ,Front line ,Hematology ,Middle Aged ,medicine.disease ,Combined Modality Therapy ,Magnetic Resonance Imaging ,Progression-Free Survival ,Histiocytosis, Langerhans-Cell ,Treatment Outcome ,Disease Progression ,Cancer research ,Drug Evaluation ,Pulmonary Diffusing Capacity ,Female ,business ,medicine.drug - Published
- 2021
- Full Text
- View/download PDF
19. Editorial Foreword
- Author
-
Jack Whitehead and Marie Huxtable
- Subjects
Theory and practice of education ,LB5-3640 ,Special aspects of education ,LC8-6691 - Abstract
EJOLTs 2023, Volume 16 is the first volume to be comprised completely by content published as soon as the Editorial Board has accepted it for publication. The change from publishing just twice a year has been introduced for a number of reasons. EJOLTs has always been a web-based journal and practitioners have been encouraged to make the best use of innovations in technology in their research and to communicate their accounts of their Living Educational Theory Research. However, EJOLTs continued to follow many of the practices of traditional print-based journals, including publishing issues at predetermined moments in time. Developments in technology and recognition and appreciation of what constitutes educational knowledge by the global Academy now open new possibilities of publishing. Hence the decision to change to publishing, as papers are ready, rather than gathering contents for issues to publish twice a year
- Published
- 2024
- Full Text
- View/download PDF
20. Pleiotropic brain function of whirlin identified by a novel mutation
- Author
-
Carlos Aguilar, Debbie Williams, Ramakrishna Kurapati, Rasneer S. Bains, Philomena Mburu, Andy Parker, Jackie Williams, Danilo Concas, Hilda Tateossian, Andrew R. Haynes, Gareth Banks, Pratik Vikhe, Ines Heise, Marie Hutchison, Gemma Atkins, Simon Gillard, Becky Starbuck, Simona Oliveri, Andrew Blake, Siddharth Sethi, Saumya Kumar, Tanaya Bardhan, Jing-Yi Jeng, Stuart L. Johnson, Lara F. Corns, Walter Marcotti, Michelle Simon, Sara Wells, Paul K. Potter, and Heena V. Lad
- Subjects
Biological sciences ,Neuroscience ,Molecular neuroscience ,Science - Abstract
Summary: Despite some evidence indicating diverse roles of whirlin in neurons, the functional corollary of whirlin gene function and behavior has not been investigated or broadly characterized. A single nucleotide variant was identified from our recessive ENU-mutagenesis screen at a donor-splice site in whirlin, a protein critical for proper sensorineural hearing function. The mutation (head-bob, hb) led to partial intron-retention causing a frameshift and introducing a premature termination codon. Mutant mice had a head-bobbing phenotype and significant hyperactivity across several phenotyping tests. Lack of complementation of head-bob with whirler mutant mice confirmed the head-bob mutation as functionally distinct with compound mutants having a mild-moderate hearing defect. Utilizing transgenics, we demonstrate rescue of the hyperactive phenotype and combined with the expression profiling data conclude whirlin plays an essential role in activity-related behaviors. These results highlight a pleiotropic role of whirlin within the brain and implicate alternative, central mediated pathways in its function.
- Published
- 2024
- Full Text
- View/download PDF
21. Cell-to-cell transmitted alpha-synuclein recapitulates experimental Parkinson’s disease
- Author
-
Natalia Cecilia Prymaczok, Pablo Nicolas De Francesco, Samanta Mazzetti, Marie Humbert-Claude, Liliane Tenenbaum, Graziella Cappelletti, Eliezer Masliah, Mario Perello, Roland Riek, and Juan Atilio Gerez
- Subjects
Neurology. Diseases of the nervous system ,RC346-429 - Abstract
Abstract Parkinson’s disease is characterized by a progressive accumulation of alpha-Synuclein (αSyn) neuronal inclusions called Lewy bodies in the nervous system. Lewy bodies can arise from the cell-to-cell propagation of αSyn, which can occur via sequential steps of secretion and uptake. Here, by fusing a removable short signal peptide to the N-terminus of αSyn, we developed a novel mouse model with enhanced αSyn secretion and cell-to-cell transmission. Expression of the secreted αSyn in the mouse brain was under the control of a novel hybrid promoter in combination with adeno-associated virus serotype 9 (AAV9). This combination of promoter and viral vector induced a robust expression in neurons but not in the glia of injected mice. Biochemical characterization of the secreted αSyn revealed that, in cultured cells, this protein is released to the extracellular milieu via conventional secretion. The released αSyn is then internalized and processed by acceptor cells via the endosome–lysosome pathway indicating that the secreted αSyn is cell-to-cell transmitted. The secreted αSyn is aggregation-prone and amyloidogenic, and when expressed in the brain of wild-type non-transgenic mice, it induces a Parkinson’s disease-like phenotype that includes a robust αSyn pathology in the substantia nigra, neuronal loss, neuroinflammation, and motor deficits, all the key features of experimental animal models of Parkinson’s disease. In summary, a novel animal model of Parkinson’s disease based on enhanced cell-to-cell transmission of αSyn was developed. The neuron-produced cell-to-cell transmitted αSyn triggers all phenotypic features of experimental Parkinson’s disease in mice.
- Published
- 2024
- Full Text
- View/download PDF
22. High-Grade B-Cell Lymphoma, Not Otherwise Specified (HGBL, NOS): Characteristics, Treatment, and Outcomes from 17 Academic US Centers
- Author
-
M. Ali Ansari-Lari, Brad M. Haverkos, Anna Kress, Andrew M. Evens, Yasmin Karimi, Adam J. Olszewski, Julie M. Vose, Adam Zayac, L. Jeffrey Medeiros, David A. Bond, Paul Rubinstein, Emily C. Ayers, Manali Kamdar, Amina Chaudhry, Mitchell E. Hughes, Karan Pandya, Shalin Kothari, Amy Beckman, Suchitra Sundaram, Mina L. Xu, Stephen D. Smith, Marie Hu, Daniel J. Landsburg, Mark Girton, Habibe Kurt, Reem Karmali, Timothy S. Oh, Heather Nutsch, Jose Sandoval-Sus, Seema Naik, Pallawi Torka, Shaoying Li, Narendranath Epperla, and Kikkeri N Naresh
- Subjects
Oncology ,medicine.medical_specialty ,business.industry ,Internal medicine ,Immunology ,High grade B-cell lymphoma ,Not Otherwise Specified ,Medicine ,Cell Biology ,Hematology ,business ,Biochemistry - Abstract
Background: The term HGBL, NOS was introduced by the World Health Organization (WHO) in 2016 for aggressive B-cell lymphomas with Burkitt lymphoma-like (BLL) or blastoid cytomorphology that lack double-hit genetics and do not meet criteria for other entities. Diagnostic patterns and prognosis of these rare tumors are not well understood. We examined the characteristics and outcomes of patients (pts) with HGBL, NOS diagnosed in 17 academic centers across the United States. Methods: We collected retrospective data on HGBL, NOS cases diagnosed by academic hematopathologists in 2017-2021; 8 centers performed a local review by lymphoma pathology experts to confirm fulfillment of the WHO criteria; pathology reports were reviewed centrally. We excluded pts not tested for MYC rearrangement (MYC-R), any double/triple-hit, diffuse large B-cell, or lymphoblastic lymphomas. Immunohistochemistry (IHC) and cytogenetic tests were done locally. Outcomes included rates of complete response (CR), progression-free (PFS) and overall survival (OS) estimated with 95% confidence intervals (CI). Results: Among 126 pts with HGBL, NOS, median age was 64 years (range 18-91), 67% were male, and 3 were HIV+. Advanced stage was present in 68%, poor performance status (PS, ECOG ≥2) in 21%, high serum lactate dehydrogenase (LDH) in 68%, extranodal (EN) sites in 79%, central nervous system (CNS) involvement in 6%, and International Prognostic Index (IPI) ≥ 3 in 55%. Cytomorphology was reported as BLL in 59 (47%) cases, blastoid in 28 (22%), and unspecified in 39 (31%). By IHC, 83% had germinal center B-cell (GCB) phenotype. Using cases with available data, CD10 was expressed in 79%, BCL6 in 81%, MUM1/IRF4 in 48%, MYC in 73%, BCL2 in 55% (dual MYC/BCL2 expressor [DEL]: 37%), CD5 in 13%, and median Ki-67 was 95%. MYC-R (single-hit) was detected in 27% (Fig A), MYC extra copies (EC) in 9%, BCL2-R in 13%, and BCL6-R in 10%. MYC-EC were present in 16% of cases with BCL2-R or BCL6-R, and BCL2/BCL6-EC in 12% of those with MYC-R. Blastoid tumors were more likely than BLL to involve >1 EN site or to have BCL2-R (Fig B). 9 cases were assessed by next generation sequencing and 5 (56%) had a TP53 mutation. Cases which underwent confirmatory pathology review (N=74) did not differ from others clinically but more often had a well-defined HGBL morphology (77% vs 58%, P=.031) and less often MYC-R (20% vs. 37%, P=.004). The most common first-line regimens (among treated pts, N=121) were DA-EPOCH-R (50%) and RCHOP (35%), with few pts receiving HyperCVAD/MA (5%) or CODOX-M±IVAC (2%); 97% received rituximab, and 44% CNS prophylaxis. Pts selected for DA-EPOCH-R vs. RCHOP were younger (median 61 vs. 68 years, P=.006), more often had stage 3/4 (P=.04), BLL morphology (56% vs. 29%, P=.009) or MYC-R (31% vs. 14%, P=.06). CR was attained in 62% of pts, whereas 20% had progressive disease. The most frequent salvage regimens (± rituximab) included ICE (N=12), DHAP (N=6), and GemOx (N=5). 3 pts underwent autologous, and 3 allogeneic transplant (2/3 subsequently relapsed). 13 received chimeric antigen receptor (CAR) T-cells, with response noted in 7 (54%) and CR in 4 (31%); HGBL relapsed in 3/7 (43%) responders. With median follow-up of 2.7 years, 39% of pts relapsed, and 33% died. Of 49 observed relapses, 13 (27%) involved the CNS. PFS estimate at 2 years was 51% (95% CI, 42-60%) and OS was 68% (95% CI, 58-76%; Fig C). PFS and OS were not significantly associated with age or PS, but stage and LDH were prognostic (Fig D-G). Furthermore, PFS did not differ by BLL/blastoid morphology, MYC-R status or DEL status, but non-GCB tumors had somewhat worse PFS (Fig H-J). We observed no significant PFS (or OS) difference between pts selected for RCHOP vs. DA-EPOCH-R (P=.83 for PFS, Fig K; P=.55 for OS) in aggregate or in any subset, except for de novo tumors with BLL morphology (N=41), where DA-EPOCH-R showed a superior 2-year PFS (73% vs 38% for RCHOP, P=.027; stratified by IPI: P=.040, Fig L). Conclusions: HGBL, NOS, as diagnosed in current academic practice, is highly heterogeneous, highlighting the need to classify high-grade lymphomas using molecular rather than morphologic features. Considering poor survival in all age groups (except for few pts with early stage and normal LDH), lack of prognostic significance of MYC-R, DEL status, or cytomorphology, HGBL, NOS needs prospective trials to delineate prognostic biomarkers, the role of intensified chemotherapy, and novel therapeutic approaches. Figure 1 Figure 1. Disclosures Landsburg: Triphase: Research Funding; Takeda: Research Funding; Curis: Research Funding; Incyte: Membership on an entity's Board of Directors or advisory committees; Karyopharm: Membership on an entity's Board of Directors or advisory committees, Other: DSMB member; ADCT: Membership on an entity's Board of Directors or advisory committees; Morphosys: Membership on an entity's Board of Directors or advisory committees. Hughes: Acerta Pharma: Research Funding; AstraZeneca: Consultancy, Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Genzyme: Consultancy; Janssen: Consultancy; Karyopharm: Membership on an entity's Board of Directors or advisory committees. Sandoval-Sus: SeaGen, Janssen, MassiveBio, TG: Other: Advisory Board; BMS: Other: Advisory Board, Speakers Bureau. Kothari: Incyte pharmaceuticals: Consultancy, Honoraria; Karyopharm pharmaceuticals: Consultancy, Honoraria. Torka: TG Therapeutics: Membership on an entity's Board of Directors or advisory committees. Smith: Acerta Pharma BV: Research Funding; ADC Therapeutics: Consultancy; AstraZeneca: Consultancy, Research Funding; De Novo Biopharma: Research Funding; Ignyta (spouse): Research Funding; Beigene: Consultancy, Research Funding; Portola Pharmaceuticals: Research Funding; Incyte: Consultancy; Incyte Corporation: Research Funding; Karyopharm: Consultancy; KITE pharm: Consultancy; Merck Sharp & Dohme Corp: Research Funding; Ayala (spouse): Research Funding; Bayer: Research Funding; Genentech: Research Funding; Bristol Myers Squibb (spouse): Research Funding; Millenium/Takeda: Consultancy. Epperla: Genzyme: Honoraria; Karyopharm: Other: Ad Board; Beigene: Speakers Bureau; Verastem: Speakers Bureau. Bond: Kite/Gilead: Honoraria. Naik: Sanofi: Other: Virtual Advisory Board Member ; Takeda: Other: Virtual Advisory Board Member ; Kite: Other: Virtual Advisory Board Member. Kamdar: ADC Therapeutics: Consultancy; AbbVie: Consultancy; KaryoPharm: Consultancy; Kite: Consultancy; Adaptive Biotechnologies: Consultancy; AstraZeneca: Consultancy; Celgene (BMS): Consultancy; TG Therapeutics: Research Funding; Genentech: Research Funding; Genetech: Other; Celgene: Other; SeaGen: Speakers Bureau. Haverkos: Viracta Therapeutics: Consultancy. Karmali: BMS/Celgene/Juno: Consultancy, Research Funding; Takeda: Research Funding; Roche: Consultancy; Epizyme: Consultancy; Janssen/Pharmacyclics: Consultancy; EUSA: Consultancy; Genentech: Consultancy; Karyopharm: Consultancy; AstraZeneca: Speakers Bureau; Kite, a Gilead Company: Consultancy, Research Funding, Speakers Bureau; Morphosys: Consultancy, Speakers Bureau; BeiGene: Consultancy, Speakers Bureau. Vose: Kite, a Gilead Company: Honoraria, Research Funding. Olszewski: PrecisionBio: Research Funding; Celldex Therapeutics: Research Funding; TG Therapeutics: Research Funding; Acrotech Pharma: Research Funding; Genentech, Inc.: Research Funding; Genmab: Research Funding.
- Published
- 2021
- Full Text
- View/download PDF
23. Predictors of Relapse and Survival Following Autologous Stem Cell Transplant in Patients with Diffuse Large B-Cell Lymphoma
- Author
-
Todd A. Fehniger, Marie Hu, Marcus Watkins, David A. Russler-Germain, Qing Cao, Saba Raya, Veronika Bachanova, and Daniel J. Weisdorf
- Subjects
Pathology ,medicine.medical_specialty ,business.industry ,Immunology ,medicine ,In patient ,Cell Biology ,Hematology ,Stem cell ,business ,medicine.disease ,Biochemistry ,Diffuse large B-cell lymphoma - Abstract
Background: Although the majority of patients with diffuse large B-cell lymphoma (DLBCL) can be cured with intensive chemotherapy and rituximab, 30-40% of patients will be refractory to or relapse after first line treatment. For these patients, the current standard of care is salvage chemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation (ASCT). Prior studies have largely examined clinical risk factors associated with higher risk of relapse after ASCT; however, there is limited data integrating both pathologic and molecular features. Thus, we aimed to identify high-risk features associated with relapse and survival after ASCT using a combination of clinical, molecular, pathologic, and transplant characteristics. Methods: We retrospectively analyzed the medical records of all adult patients with DLBCL who underwent ASCT at our two institutions from 2010 to 2020. Patients with primary CNS lymphoma, primary mediastinal B-cell lymphoma, or Burkitt lymphoma were excluded. We analyzed demographics, clinical characteristics, cell of origin (COO) by immunohistochemistry (IHC), fluorescence in-situ hybridization (FISH) testing, and treatment/transplant characteristics. The primary endpoints were 3-year progression-free survival (PFS) and overall survival (OS) from ASCT. The Kaplan-Meier method was used to estimate survival with univariate and multivariate Cox proportional hazards regression performed to identify factors associating with PFS and OS, summarized using hazard ratios (HR) with 95% confidence intervals (CI). Results: A total of 235 DLBCL patients underwent ASCT from 2010 to 2020. Median age at ASCT was 61 years (range: 25-75) and 63% were male. At DLBCL diagnosis, 80% had advanced stage disease, 74% had extranodal involvement, 13% had poor performance status, and 65% had elevated lactate dehydrogenase (LDH). 71 patients (30%) had a prior or concurrent indolent lymphoma diagnosis indicating transformed disease. Of the patients with available COO and molecular data, 115 (60%) had germinal center B-cell (GCB) phenotype by IHC, 10 (6%) had a single MYC rearrangement by FISH, and 35 (22%) had MYC plus BCL2 and/or BCL6 rearrangements (DHL/THL). After first-line treatment, 12% remained refractory and 62% later relapsed at a median of 13 months (range: 1-240). Patients received a median of 2 (range: 1-5) lines of treatment pre-ASCT. At time of ASCT, 66% were in complete response (CR) and 32% were in partial response (PR) by standard of care imaging and response criteria. With median follow-up of 5.2 years from time of ASCT, 98 patients (42%) relapsed and 78 (33%) died. 3-year PFS and OS were 58% (95% CI 51-64%) and 74% (95% CI 67-79%), respectively. In univariate analysis, factors associated with worse PFS and worse OS included 3 or more lines of treatment pre-ASCT (p60 at ASCT (HR 1.92, 95% CI 1.06-3.47, p=0.03) (Figure 1C). Stratifying by COO and disease status at transplant, 3-year OS was best in the GCB/CR group (84%, 95% CI 73-90%), while worse but similar in the GCB/non-CR and non-GCB/CR groups (68%, 95% CI 51-80% and 71%, 95% CI 56-83%, respectively) (Figure 1D). The non-GCB/non-CR group had the worst 3-year OS (48%, 95% CI 27-67%). No individual factors beyond CR/non-CR at ASCT were associated with worse 3-year PFS. Notably, DHL/THL patients (77% of whom were in CR at time of ASCT) had similar PFS (p=0.08) and OS (p=0.30) to non-DHL/THL patients, suggesting that response to therapy may be more prognostic than high-risk molecular features alone. Conclusions: This analysis indicated that factors associated with OS after ASCT were disease status at time of transplant and COO, with non-GCB patients not in CR having the poorest outcomes. GCB patients not in CR were still able to be cured by ASCT at a high rate. Molecular rearrangements including DHL/THL were not prognostic, although interpretation may be limited by the modest number of DHL/THL patients. These findings may inform which patients should undergo ASCT, while the highest risk group may be better treated with alternatives including novel targeted agents or chimeric antigen receptor cell therapy. Figure 1 Figure 1. Disclosures Bachanova: FATE: Membership on an entity's Board of Directors or advisory committees, Research Funding; Incyte: Research Funding; KaryoPharma: Membership on an entity's Board of Directors or advisory committees; Gamida Cell: Membership on an entity's Board of Directors or advisory committees, Research Funding. Fehniger: Compass Therapeutics: Research Funding; Affimed: Research Funding; ImmunityBio: Research Funding; Wugen: Consultancy, Current equity holder in publicly-traded company, Patents & Royalties: related to memory like NK cells, Research Funding; OrcaBio: Other; Kiadis: Other; HCW Biologics: Research Funding; Indapta: Other. Weisdorf: Fate Therapeutics: Research Funding; Incyte: Research Funding.
- Published
- 2021
- Full Text
- View/download PDF
24. Phenotypes and prognostic factors in adults with Langerhans cell histiocytosis
- Author
-
Karen L. Rech, Ronald S. Go, Gaurav Goyal, Aldo A. Acosta-Medina, Caroline J. Davidge-Pitts, Jason R. Young, N. Nora Bennani, Jay H. Ryu, Marie Hu, Aishwarya Ravindran, Mithun Vinod Shah, Robert Vassallo, Jithma P. Abeykoon, and W. Oliver Tobin
- Subjects
Cancer Research ,Pathology ,medicine.medical_specialty ,Oncology ,Langerhans cell histiocytosis ,business.industry ,medicine ,Disease ,medicine.disease ,business ,Phenotype - Abstract
7049 Background: Langerhans cell histiocytosis (LCH) can manifest as single system (SS) disease, multisystem (MS) disease, or pulmonary LCH (smoking-related). There is a paucity of data on prognostic factors including risk organ (RO) involvement (liver, spleen, and bone marrow) in adult LCH, which we sought to address in this study. Methods: Single-center retrospective study of patients ≥18y diagnosed with LCH from 1998 to 2020. Univariate and multivariate analyses for progression free survival (PFS) and overall survival (OS) were conducted using age, sex, organ involvement, LCH subtype, year of diagnosis, BRAF V600E status, and treatments. Results: We included 219 patients with LCH; median age 43y (range 19-88), females 51%, SS unifocal (23%), SS multifocal (6%), pulmonary (31%) and MS (40%). Commonly involved organs included lung (53%), bone (42%), skin (24%), pituitary (16%), and CNS (12%). BRAF V600E was positive in 40/88 (46%). Median follow-up duration was 6.1y (95% CI, 5.1- 7.1). On univariate analysis, factors associated with worse PFS were bone LCH, RO involvement, multifocal/MS LCH, and radiation therapy alone; those with worse OS included RO involvement, MS disease, BRAF V600E+, and age ≥45y at diagnosis. In multivariate analysis, BRAF V600E and age ≥45y at diagnosis were associated with worse mortality (Table). Median PFS was not reached (NR-NR) for SS unifocal LCH, 5mo (0-12.7) for SS multifocal LCH, 110mo (84.7-135.3) for pulmonary LCH, and 27mo (17.2-36.8) for MS LCH. 5-year OS was 97.4% for SS unifocal LCH, 100% for SS multifocal LCH, 96.1% for pulmonary LCH, and 79.9% for MS LCH. 41 (18.7%) developed a second primary malignancy (SPM), of which 11 were hematologic neoplasms. There was a trend towards a higher prevalence of SPMs in patients with BRAF V600E (28% vs. 17%; p = 0.22). Conclusions: In our large single-center study, PFS for multifocal and MS LCH was worse than SS unifocal or pulmonary LCH. RO involvement was not associated with outcomes in multivariate analysis. Overall prognosis was excellent for all subtypes except MS LCH. BRAF V600E and older age were associated with worse OS. The prevalence of SPMs was very high and needs to be explored further.[Table: see text]
- Published
- 2021
- Full Text
- View/download PDF
25. Soigner les malades au xve siècle. L’exemple de la fouille de l’hôtel-Dieu de Valenciennes (Nord)
- Author
-
David Delassus, Marie Derreumaux, Dominique Frere, Marie Huin, Hélène Poirier, Tarek Oueslati, Coralie Favero, Arnaud Tixador, Maxime Rageot, Delphine Barbier-Pain, Matthieu Deltombe, Patrice Korpiun, Martin Laugero, and Nima Saedlou
- Subjects
hospital ,cave ,water tank ,latrines ,ceramography ,carpology ,Archaeology ,CC1-960 - Abstract
Abstract: The Hôtel-Dieu in Valenciennes was excavated in 2016 by the municipal archaeological service. This excavation was a unique opportunity to record the medieval state of the hospital founded in 1430, only known beforehand through written and iconographical sources. The excavation mainly uncovered the western part of the main building. The construction analysis revealed that the sick ward and the chapel didn’t originally occupy the whole building, as the newly uncovered western part housed a semi-excavated space, taking a third of the building. Other arrangements of that same building (water tank, cave) show a will to facilitate the work of nurses by accommodating the requirements of the spiritual as well as the physical aspects of healing. The results must have been found efficient by contemporaries, as it later influenced the construction of the large building of the hospices in Beaune. Last, the excavation of two closed spaces gave various information about the material environment of the sick and their healers, as well as other aspects of healing: food, hygiene, medicine. Two glass sprinklers discovered showed the influence of the Arabic world on the equipment of the hospital in the 15th c.
- Published
- 2023
- Full Text
- View/download PDF
26. CRISPR/Cas9-mediated knock-in of BRCA1/2 mutations restores response to olaparib in pancreatic cancer cell lines
- Author
-
Andréa Witz, Julie Dardare, Aurélie Francois, Marie Husson, Marie Rouyer, Jessica Demange, Jean-Louis Merlin, Pauline Gilson, and Alexandre Harlé
- Subjects
Medicine ,Science - Abstract
Abstract Pancreatic cancer is one of the most aggressive diseases with a very poor outcome. Olaparib, a PARP inhibitor, as maintenance therapy showed benefits in patients with metastatic pancreatic adenocarcinoma bearing germline BRCA1/2 mutations. However, germline BRCA mutation has been described in only 4–7% of patients with pancreatic adenocarcinoma. A CRISPR/Cas9-mediated system was used to knock-in the c.763G > T p.(Glu255*) and c.2133C > A p.(Cys711*) mutations in cell lines to obtain truncated BRCA1 and BRCA2 proteins, respectively. A CRISPR/Cas9 ribonucleoprotein complex was assembled for each mutation and transfected into two pancreatic cell lines (T3M4 and Capan-2) and into a breast cancer cell lines (MCF7) as control. BRCA protein levels were significantly decreased in all BRCA-depleted cells (P
- Published
- 2023
- Full Text
- View/download PDF
27. Stability and biological response of PEGylated gold nanoparticles
- Author
-
Hoang Yen Nguyenova, Marie Hubalek Kalbacova, Marcela Dendisova, Miriama Sikorova, Jaroslava Jarolimkova, Zdenka Kolska, Lucie Ulrychova, Jan Weber, and Alena Reznickova
- Subjects
Nanoparticle ,Gold ,Polyethylene glycol ,Stability ,Cytotoxicity ,Antiviral activity ,Science (General) ,Q1-390 ,Social sciences (General) ,H1-99 - Abstract
Stability and cytotoxicity of PEGylated Au NPs is crucial for biomedical application. In this study, we have focused on thermal stability of PEGylated Au NPs at 4 and 37 °C and after sterilization in autoclave. Gold nanoparticles were prepared by direct sputtering of gold into PEG and PEG-NH2. Transmission electron microscopy revealed that NPs exhibit a spherical shape with average dimensions 3.8 nm for both AuNP_PEG and AuNP_PEG-NH2. The single LSPR band at wavelength of 509 nm also confirmed presence of spherical Au NPs in both cases. Moreover, according to UV–Vis spectra, the Au NPs were overall stable during aging or thermal stressing and even after sterilization in autoclave. Based on gel electrophoresis results, the higher density of functionalizing ligands and the higher stability is assumed on AuNP_PEG-NH2. Changes in concentration of gold did not occur after thermal stress or with aging. pH values have to be adjusted to be suitable for bioapplications – original pH values are either too alkaline (AuNP_PEG-NH2, pH 10) or too acidic (AuNP_PEG, pH 5). Cytotoxicity was tested on human osteoblasts and fibroblasts. Overall, both Au NPs have shown good cytocompatibility either freshly prepared or even after Au NPs′ sterilization in the autoclave. Prepared Au NP dispersions were also examined for their antiviral activity, however no significant effect was observed. We have synthesized highly stable, non-cytotoxic PEGylated Au NPs, which are ready for preclinical testing.
- Published
- 2024
- Full Text
- View/download PDF
28. SCOPE: predicting future diagnoses in office visits using electronic health records
- Author
-
Pritam Mukherjee, Marie Humbert-Droz, Jonathan H. Chen, and Olivier Gevaert
- Subjects
Medicine ,Science - Abstract
Abstract We propose an interpretable and scalable model to predict likely diagnoses at an encounter based on past diagnoses and lab results. This model is intended to aid physicians in their interaction with the electronic health records (EHR). To accomplish this, we retrospectively collected and de-identified EHR data of 2,701,522 patients at Stanford Healthcare over a time period from January 2008 to December 2016. A population-based sample of patients comprising 524,198 individuals (44% M, 56% F) with multiple encounters with at least one frequently occurring diagnosis codes were chosen. A calibrated model was developed to predict ICD-10 diagnosis codes at an encounter based on the past diagnoses and lab results, using a binary relevance based multi-label modeling strategy. Logistic regression and random forests were tested as the base classifier, and several time windows were tested for aggregating the past diagnoses and labs. This modeling approach was compared to a recurrent neural network based deep learning method. The best model used random forest as the base classifier and integrated demographic features, diagnosis codes, and lab results. The best model was calibrated and its performance was comparable or better than existing methods in terms of various metrics, including a median AUROC of 0.904 (IQR [0.838, 0.954]) over 583 diseases. When predicting the first occurrence of a disease label for a patient, the median AUROC with the best model was 0.796 (IQR [0.737, 0.868]). Our modeling approach performed comparably as the tested deep learning method, outperforming it in terms of AUROC (p
- Published
- 2023
- Full Text
- View/download PDF
29. Metabolite Variations during the First Weeks of Growth of Immature Citrus sinensis and Citrus reticulata by Untargeted Liquid Chromatography–Mass Spectrometry/Mass Spectrometry Metabolomics
- Author
-
Estelle Deschamps, Marie Durand-Hulak, Denis Castagnos, Marie Hubert-Roux, Isabelle Schmitz, Yann Froelicher, and Carlos Afonso
- Subjects
immature ,Citrus sinensis ,orange ,Citrus reticulata ,mandarin ,metabolomics ,Organic chemistry ,QD241-441 - Abstract
Immature citruses are an important resource for the pharmaceutical industry due to their high levels of metabolites with health benefits. In this study, we used untargeted liquid chromatography–mass spectrometry (LC-MS) metabolomics to investigate the changes associated with fruit size in immature citrus fruits in the first weeks of growth. Three orange cultivars (Citrus sinensis ‘Navel’, Citrus sinensis ‘Valencia’, and Citrus sinensis ‘Valencia Late’) and a mandarin (Citrus reticulata Blanco ‘Fremont’) were separated into eight fruit sizes, extracted, and analyzed. Statistical analyses revealed a distinct separation between the mandarin and the oranges based on 56 metabolites, with an additional separation between the ‘Navel’ orange and the ‘Valencia’ and ‘Valencia Late’ oranges based on 21 metabolites. Then, metabolites that evolved significantly with fruit size growth were identified, including 40 up-regulated and 31 down-regulated metabolites. This study provides new insights into the metabolite modifications of immature Citrus sinensis and Citrus reticulata in the first weeks of growth and emphasizes the significance of including early sampled fruits in citrus maturation studies.
- Published
- 2024
- Full Text
- View/download PDF
30. Long-read sequencing for fast and robust identification of correct genome-edited alleles: PCR-based and Cas9 capture methods.
- Author
-
Christopher V McCabe, Peter D Price, Gemma F Codner, Alasdair J Allan, Adam Caulder, Skevoulla Christou, Jorik Loeffler, Matthew Mackenzie, Elke Malzer, Joffrey Mianné, Krystian J Nowicki, Edward J O'Neill, Fran J Pike, Marie Hutchison, Benoit Petit-Demoulière, Michelle E Stewart, Hilary Gates, Sara Wells, Nicholas D Sanderson, and Lydia Teboul
- Subjects
Genetics ,QH426-470 - Abstract
BackgroundRecent developments in CRISPR/Cas9 genome-editing tools have facilitated the introduction of precise alleles, including genetic intervals spanning several kilobases, directly into the embryo. However, the introduction of donor templates, via homology directed repair, can be erroneous or incomplete and these techniques often produce mosaic founder animals. Thus, newly generated alleles must be verified at the sequence level across the targeted locus. Screening for the presence of the desired mutant allele using traditional sequencing methods can be challenging due to the size of the interval to be sequenced, together with the mosaic nature of founders.Methodology/principal findingsIn order to help disentangle the genetic complexity of these animals, we tested the application of Oxford Nanopore Technologies long-read sequencing at the targeted locus and found that the achievable depth of sequencing is sufficient to offset the sequencing error rate associated with the technology used to validate targeted regions of interest. We have assembled an analysis workflow that facilitates interrogating the entire length of a targeted segment in a single read, to confirm that the intended mutant sequence is present in both heterozygous animals and mosaic founders. We used this workflow to compare the output of PCR-based and Cas9 capture-based targeted sequencing for validation of edited alleles.ConclusionTargeted long-read sequencing supports in-depth characterisation of all experimental models that aim to produce knock-in or conditional alleles, including those that contain a mix of genome-edited alleles. PCR- or Cas9 capture-based modalities bring different advantages to the analysis.
- Published
- 2024
- Full Text
- View/download PDF
31. Factors associated with satisfaction with social roles and activities among people with systemic sclerosis: a Scleroderma Patient-centered Intervention Network (SPIN) cohort cross-sectional study
- Author
-
Arsène Mekinian, Thierry Martin, Eric Hachulla, Carter Thorne, Danielle Rice, Andrea Benedetti, Brooke Levis, Virginia Steen, Paul R Fortin, Vincent Poindron, Aurélien Guffroy, David Launay, Luc Mouthon, Mandana Nikpour, John Varga, Benjamin Chaigne, Sindhu R Johnson, Sébastien Rivière, Michael Hughes, Daphna Harel, Marie-Eve Carrier, Karen Nielsen, Susan J Bartlett, Karen Gottesman, Ghassan El-Baalbaki, Kim Fligelstone, Catherine Fortune, Tracy Frech, Marie Hudson, Maggie Larche, Catarina Leite, Janet Pope, Anne A Schouffoer, Maria E Suarez-Almazor, Christian Agard, Marc André, Sabine Berthier, Lyne Bissonnette, Alessandra Bruns, Patricia Carreira, Marion Casadevall, Lorinda Chung, Christopher Denton, Robyn Domsic, James V Dunne, Bertrand Dunogue, Regina Fare, Dominique Farge-bancel, Jessica Gordon, Brigitte Granel-Rey, Genevieve Gyger, Monique Hinchcliff, Alena Ikic, Niall Jones, Suzanne Kafaja, Nader Khalidi, Marc Lambert, Hélène Maillard, Joanne Manning, Ariel Masetto, François Maurier, Susanna Proudman, Alexis Régent, David Robinson, Sophie Roux, Perrine Smets, Vincent Sobanski, Robert Spiera, Evelyn Sutton, Pearce Wilcox, Laurent Alric, Grégory Pugnet, François Rannou, Amy Gietzen, Christelle Nguyen, Michelle Richard, Nancy Maltez, Isabelle Marie, Mara Cañedo Ayala, Geneviève Guillot, Elana J Bernstein, Brett Thombs, Paul Legendre, Thylbert Deltombe, Sabrina Hoa, Laura K Hummers, Sophie Blaise, Yvonne C Lee, Louis Olagne, Marie-Claude Geoffroy, Richard S Henry, Robyn Wojeck, Maureen Mayes, Tiffany Dal Santo, Kimberly Lakin, Gabrielle Virgili-Gervais, Vanessa Malcarne, Claire E Adams, Rodriguez-Reyna Tatiana Sofia, Floryan Beaslay, Eva Bories, Carlotta Cacciatore, Benjamin Crichi, Tannvir Desroche, Loraine Gauzère, Anne Gerber, Maria Martin Lopez, Sheila Melchor Díaz, Morgane Mourguet, Loïc Raffray, Frederic Renou, Esther Rodríguez Almazar, Damien Vagner, Vanessa Cook, Sophie Hu, Elsa-Lynn Nassar, Marieke Alexandra Neyer, and Sabrina Provencher
- Subjects
Medicine - Abstract
Objective The objectives were to (1) compare satisfaction with social roles and activities in a large multinational systemic sclerosis (SSc) cohort to general population normative data and (2) identify sociodemographic, lifestyle and SSc disease factors associated with satisfaction with social roles and activities.Methods Participants in the Scleroderma Patient-centered Intervention Network Cohort completed the Patient Reported Outcomes Information System Version 2 satisfaction with social roles and activities domain questionnaire. Multivariable regression was used to assess associations with sociodemographic, lifestyle and disease factors.Results Among 2385 participants, mean satisfaction with social roles and activities T-score (48.1, SD=9.9) was slightly lower than the US general population (mean=50, SD=10). Factors independently associated with satisfaction were years of education (0.54 per SD, 95% CI 0.14 to 0.93); non-White race or ethnicity (−1.13, 95% CI −2.18 to –0.08); living in Canada (−1.33, 95% CI −2.40 to –0.26 (reference USA)) or the UK (−2.49, 95% CI −3.92 to –1.06); body mass index (−1.08 per SD, 95% CI −1.47 to –0.69); gastrointestinal involvement (−3.16, 95% CI −4.27 to –2.05); digital ulcers (−1.90, 95% CI −3.05 to –0.76); moderate (−1.62, 95% CI −2.78 to –0.45) or severe (−2.26, 95% CI −3.99 to –0.52) small joint contractures; interstitial lung disease (−1.11, 95% CI −1.97 to –0.25); pulmonary arterial hypertension (−2.69, 95% CI −4.08 to –1.30); rheumatoid arthritis (−2.51, 95% CI −4.28 to –0.73); and Sjogren’s syndrome (−2.42, 95% CI −3.96 to –0.88).Conclusion Mean satisfaction with social roles and activities is slightly lower in SSc than the general population and associated with multiple sociodemographic and disease factors.
- Published
- 2024
- Full Text
- View/download PDF
32. Characterisation and prion transmission study in mice with genetic reduction of sporadic Creutzfeldt-Jakob disease risk gene Stx6
- Author
-
Emma Jones, Elizabeth Hill, Jacqueline Linehan, Tamsin Nazari, Adam Caulder, Gemma F. Codner, Marie Hutchison, Matthew Mackenzie, Michael Farmer, Thomas Coysh, Michael Wiggins De Oliveira, Huda Al-Doujaily, Malin Sandberg, Emmanuelle Viré, Thomas J. Cunningham, Emmanuel A. Asante, Sebastian Brandner, John Collinge, and Simon Mead
- Subjects
Prion disease ,Creutzfeldt-Jakob disease ,SNARE ,Syntaxin-6 ,Incubation period ,Neurosciences. Biological psychiatry. Neuropsychiatry ,RC321-571 - Abstract
Sporadic Creutzfeldt-Jakob disease (sCJD), the most common human prion disease, is thought to occur when the cellular prion protein (PrPC) spontaneously misfolds and assembles into prion fibrils, culminating in fatal neurodegeneration. In a genome-wide association study of sCJD, we recently identified risk variants in and around the gene STX6, with evidence to suggest a causal increase of STX6 expression in disease-relevant brain regions. STX6 encodes syntaxin-6, a SNARE protein primarily involved in early endosome to trans-Golgi network retrograde transport. Here we developed and characterised a mouse model with genetic depletion of Stx6 and investigated a causal role of Stx6 expression in mouse prion disease through a classical prion transmission study, assessing the impact of homozygous and heterozygous syntaxin-6 knockout on disease incubation periods and prion-related neuropathology. Following inoculation with RML prions, incubation periods in Stx6−/− and Stx6+/− mice differed by 12 days relative to wildtype. Similarly, in Stx6−/− mice, disease incubation periods following inoculation with ME7 prions also differed by 12 days. Histopathological analysis revealed a modest increase in astrogliosis in ME7-inoculated Stx6−/− animals and a variable effect of Stx6 expression on microglia activation, however no differences in neuronal loss, spongiform change or PrP deposition were observed at endpoint. Importantly, Stx6−/− mice are viable and fertile with no gross impairments on a range of neurological, biochemical, histological and skeletal structure tests. Our results provide some support for a pathological role of Stx6 expression in prion disease, which warrants further investigation in the context of prion disease but also other neurodegenerative diseases considering syntaxin-6 appears to have pleiotropic risk effects in progressive supranuclear palsy and Alzheimer's disease.
- Published
- 2024
- Full Text
- View/download PDF
33. 29-Year-Old Woman With Fever and Bilateral Lower Extremity Lesions
- Author
-
Derek Ebner, Marie Hu, and Thomas H. Poterucha
- Subjects
Adult ,medicine.medical_specialty ,medicine.diagnostic_test ,Fever ,business.industry ,Biopsy, Needle ,MEDLINE ,Furunculosis ,General Medicine ,Methylprednisolone ,Pyoderma Gangrenosum ,Diagnosis, Differential ,Text mining ,Lower Extremity ,Biopsy ,medicine ,Humans ,Female ,Radiology ,Obesity ,business - Published
- 2017
34. Novel insights into systemic sclerosis using a sensitive computational method to analyze whole-genome bisulfite sequencing data
- Author
-
Jeffrey C. Y. Yu, Yixiao Zeng, Kaiqiong Zhao, Tianyuan Lu, Kathleen Oros Klein, Inés Colmegna, Maximilien Lora, Sahir R. Bhatnagar, Andrew Leask, Celia M. T. Greenwood, and Marie Hudson
- Subjects
Scleroderma ,Systemic sclerosis ,DNA methylation ,Whole genome bisulfite sequencing ,Differentially methylated regions ,Smoothing ,Medicine ,Genetics ,QH426-470 - Abstract
Abstract Background Abnormal DNA methylation is thought to contribute to the onset and progression of systemic sclerosis. Currently, the most comprehensive assay for profiling DNA methylation is whole-genome bisulfite sequencing (WGBS), but its precision depends on read depth and it may be subject to sequencing errors. SOMNiBUS, a method for regional analysis, attempts to overcome some of these limitations. Using SOMNiBUS, we re-analyzed WGBS data previously analyzed using bumphunter, an approach that initially fits single CpG associations, to contrast DNA methylation estimates by both methods. Methods Purified CD4+ T lymphocytes of 9 SSc and 4 control females were sequenced using WGBS. We separated the resulting sequencing data into regions with dense CpG data, and differentially methylated regions (DMRs) were inferred with the SOMNiBUS region-level test, adjusted for age. Pathway enrichment analysis was performed with ingenuity pathway analysis (IPA). We compared the results obtained by SOMNiBUS and bumphunter. Results Of 8268 CpG regions of ≥ 60 CpGs eligible for analysis with SOMNiBUS, we identified 131 DMRs and 125 differentially methylated genes (DMGs; p-values less than Bonferroni-corrected threshold of 6.05–06 controlling family-wise error rate at 0.05; 1.6% of the regions). In comparison, bumphunter identified 821,929 CpG regions, 599 DMRs (of which none had ≥ 60 CpGs) and 340 DMGs (q-value of 0.05; 0.04% of all regions). The top ranked gene identified by SOMNiBUS was FLT4, a lymphangiogenic orchestrator, and the top ranked gene on chromosome X was CHST7, known to catalyze the sulfation of glycosaminoglycans in the extracellular matrix. The top networks identified by IPA included connective tissue disorders. Conclusions SOMNiBUS is a complementary method of analyzing WGBS data that enhances biological insights into SSc and provides novel avenues of investigation into its pathogenesis.
- Published
- 2023
- Full Text
- View/download PDF
35. Clinical Features and Outcomes of Unifocal Adult Langerhans Cell Histiocytosis
- Author
-
Karen L. Rech, N. Nora Bennani, Gaurav Goyal, Jay H. Ryu, Marie Hu, Robert Vassallo, Mithun Vinod Shah, Ronald S. Go, and Jason R. Young
- Subjects
Pathology ,medicine.medical_specialty ,Second line treatment ,business.industry ,Immunology ,Complete remission ,Myeloproliferative disease ,Signs and symptoms ,Cell Biology ,Hematology ,Adult Langerhans Cell Histiocytosis ,Biochemistry ,Therapeutic immunosuppression ,Medicine ,business ,Cladribine ,Histiocyte ,medicine.drug - Abstract
Purpose: Langerhans cell histiocytosis (LCH) is a rare histiocytic disorder that presents with a wide spectrum of clinical diseases, ranging from single-organ lesions to systemic disease. Although previously thought of as an immune disorder, LCH was reclassified as an inflammatory myeloid neoplasm in the 2016 Histocyte Society classification after discovery of BRAF V600E or MAP2K1 gain-of-function mutations and evidence of clonality in most LCH patients. In this revised classification, LCH was divided into single-system LCH, pulmonary LCH, or multisystem LCH. However, there is a lack of data on clinical features and outcomes in the subgroup of "unifocal" non-pulmonary LCH in adults. In this study, we sought to address the gaps in knowledge for unifocal adult LCH utilizing our institution's experience over 20 years. Methods: We retrospectively reviewed the medical records of 189 adult patients (defined as >18 years old at diagnosis) with histopathologically confirmed LCH who were seen at our tertiary referral center between 1997 and 2018. Of these, 44 met criteria for unifocal LCH at diagnosis after careful exclusion of other sites of disease involvement. Results: We included 44 adult patients with unifocal LCH at diagnosis, with median age 42 years (range 19 to 88) and 55% males. 84% were Caucasians and 50% were smokers. Most commonly involved disease sites included bone (43%), skin (25%), pituitary (14%), and gastrointestinal (11%), with common presenting symptoms of head pain/swelling (25%), skin rash (20%), abdominal pain/diarrhea (11%), and diabetes insipidus (9%). Resection/excision was the most common first line therapy in 24 patients (63%); none had local recurrence and 3 patients developed recurrence at a new site. Radiation was the second most common therapy in 6 patients, with an overall response rate of 83%; none had local recurrence and 1 patient had recurrence at a new site. Other less common first-line treatments included resection followed by radiation (2), topical immunosuppression (2), dexamethasone (1), cladribine (1), smoking cessation (1), and observation (1) (Table 1). Cladribine used as first-line therapy for pituitary LCH resulted in progressive disease, but cladribine used as second-line therapy in 2 cases (including one who had progressed to multisystem disease) resulted in partial remission with no further recurrence in both cases. Patients were followed for a median of 3.8 years (range 0.1 to 18.8), with 5 patients lost to follow-up. By time of last follow-up, 11 (28%) had developed recurrence: 1 had local recurrence, 5 developed disease at a new site within the same system (skin or bone), and 5 developed multisystem disease (Figure 1). Median time to recurrence was 2 years (range 0.2 to 6.6). 2 out of 5 patients tested for BRAF had a V600E mutation, both of whom had isolated unifocal bone disease and remained in complete remission following resection at time of last follow-up. Median overall survival (OS) from time of diagnosis was not reached and overall 5-year OS was 94%. 3 patients died, only 1 of progressive LCH. Conclusion: In our study, most patients with unifocal adult LCH achieved a complete remission with surgical resection or local radiation. None of the patients treated with resection or radiation developed local recurrence, but around 1 in 5 developed distant recurrence within 5 years. However, the overall prognosis was very good, and none of the patients in the cohort progressed to "high-risk" organ (liver, spleen, or bone marrow) involvement or pulmonary involvement. Further studies are warranted to assess the role of MAPK-ERK mutations in the prognosis of unifocal LCH. Disclosures Bennani: Seattle Genetics: Other: Advisory board; Adicet Bio: Other: Advisory board; Adicet Bio: Other: Advisory board; Adicet Bio: Other: Advisory board; Kite Pharma: Other: Advisory board; Kite Pharma: Other: Advisory board; Kite Pharma: Other: Advisory board; Purdue Pharma: Other: Advisory board; Seattle Genetics: Other: Advisory board; Purdue Pharma: Other: Advisory board; Seattle Genetics: Other: Advisory board; Purdue Pharma: Other: Advisory board; Bristol-Myers Squibb: Research Funding; Bristol-Myers Squibb: Research Funding; Bristol-Myers Squibb: Research Funding. Vassallo:Sun Pharmaceuticals: Research Funding; Sun Pharmaceuticals: Research Funding; Pfizer: Research Funding; Bristol Myers Squibb: Research Funding; Bristol Myers Squibb: Research Funding.
- Published
- 2019
- Full Text
- View/download PDF
36. Single-Agent Cladribine As an Effective Therapy for Adults with Langerhans Cell Histiocytosis
- Author
-
Gaurav Goyal, Robert Vassallo, Mithun Vinod Shah, Jay H. Ryu, Marie Hu, Jithma P. Abeykoon, Nora N Bennani, and Ronald S. Go
- Subjects
medicine.medical_specialty ,Gastrointestinal bleeding ,business.industry ,Immunology ,Cell Biology ,Hematology ,medicine.disease ,Biochemistry ,Gastroenterology ,Nitrogen mustard ,chemistry.chemical_compound ,chemistry ,Langerhans cell histiocytosis ,Internal medicine ,Cohort ,medicine ,Progression-free survival ,Cladribine ,Adverse effect ,business ,Progressive disease ,medicine.drug - Abstract
Introduction Langerhans cell histiocytosis (LCH) is an uncommon histiocytic disorder which is now categorized as a hematopoietic neoplasm. Most treatment and outcomes data in LCH are derived from pediatric studies, and there is a lack of FDA-approved treatment options for adult LCH. There is some evidence that cladribine may be toxic to monocytes and monocyte-derived dendritic cells. In this study, we report the efficacy of cladribine in adult LCH patients seen at our institution. Methods We retrospectively reviewed the charts of all LCH patients seen at our institution between 1998 and 2018. Where necessary, the radiological images and histopathological slides were reviewed by an expert radiologist and pathologist. Since prospective uniform response assessment was not performed, we utilized the clinical documentation and radiological reports to assess the overall response rate (ORR). All time to event analyses were performed from the time of cladribine initiation. Results We included a total of 37 adult LCH patients in the study. The median age at diagnosis for this cohort was 35 years (range, 21-76), and 51% were males. Although 31 (84%) patients had multi-system disease, all patients had more than one LCH lesion (multifocal). Most commonly involved organs were bone (65%), lung (60%), skin (38%), lymph nodes (30%), and pituitary/hypothalamus (27%). BRAF-mutational analysis was performed in 13 patients, with 7 (54%) demonstrating the presence of BRAF-V600E mutation. Cladribine was administered as first line therapy in 22 (59%) patients and subsequent line treatment in 15 (41%). Of the 15 patients who received cladribine in subsequent line, surgery (n=3), radiation (n=3), steroids (n=3), antibiotic with inhaled steroids (n=1), vinblastine (n=3), topical nitrogen mustard cream (n=1) and vemurafenib (n=1) were the treatments utilized before the initiation of cladribine. Two patients received the drug more than once during the course of their disease. The dosing of cladribine for all patients was based on one of the two intravenous regimens (0.14 mg/kg for days 1-5 every 28 days or 5 mg/m2 for days 1-5 every 28 days). The median follow-up for the entire cohort was 4.5 years (95% CI:2-7) and the treatment outcomes are shown in Table 1. Median number of cycles of cladribine administered was 1.5 (range, 1-9). Clinical/radiographic responses were noted in 29 (78%) patientsORR was 78%, with 24% complete responses and 54% partial responses (PR). Responses were seen in various disease sites: lung nodules/infiltrates (13/29, 45%), bone (12/29, 41%), lymph nodes (8/29, 28%), skin (3/29, 10%), pituitary/hypothalamus (4/29, 14%). Eight (22%) patients did not respond and had progressive disease (PD)- cystic/bullous lung disease (n=2), skin (n=2), abdominal/peritoneal lymph nodes (n=2), and hypothalamus (n=3).The treatment was well tolerated, with grade 3 or above adverse effects seen in three patients: two with lymphopenia requiring dose delays and one with congestive cardiac failure leading to drug discontinuation. After initial disease response, PD was seen in three patients. 89%, 78%, 64% of those who responded initially maintained their responses at years 1, 3, and 5, respectively (Table 1). The 5-year progression free survival (PFS) was 55% for the entire cohort. BRAF-status was evaluated on 13 of 37 patients in the entire cohort (35%): BRAFV600E positive [n=7 (53%)] and WT [n=6 (46%)]. Of the 7 patients who had BRAFV600E mutation, responses were seen in 71%, while 100% of those without BRAFV600E achieved a response (p=0.09). At the time of last follow-up, 9 patients (24%) were dead. Of those, cause of death were available on 5 patients; due to LCH (n=1), stroke (n=1), gastrointestinal hemorrhage (n=1), acute myeloid leukemia (n=2). Conclusion In our study, cladribine monotherapy yielded a high ORR, with the majority of patients achieving a PR. The responses were durable with a small risk of subsequent disease relapse. Responses were seen irrespective of the presence of BRAFV600E mutation. Cladribine was well tolerated overall, and may be considered a potential therapy for adult LCH patients. Disclosures Vassallo: Sun Pharmaceuticals: Research Funding; Pfizer: Research Funding; Bristol Myers Squibb: Research Funding; Sun Pharmaceuticals: Research Funding; Bristol Myers Squibb: Research Funding. OffLabel Disclosure: Cladribine for langerhans cell histiocytosis
- Published
- 2019
- Full Text
- View/download PDF
37. Adult Langerhans cell histiocytosis: A contemporary single-institution series of 186 patients
- Author
-
Karen L. Rech, Robert Vassallo, Marie Hu, Mithun Vinod Shah, N. Nora Bennani, Jason R. Young, Jay H. Ryu, Gaurav Goyal, and Ronald S. Go
- Subjects
Cancer Research ,Pathology ,medicine.medical_specialty ,business.industry ,Adult Langerhans Cell Histiocytosis ,medicine.disease ,03 medical and health sciences ,Histiocytic neoplasm ,0302 clinical medicine ,Oncology ,Langerhans cell histiocytosis ,030220 oncology & carcinogenesis ,Medicine ,Single institution ,business ,030215 immunology - Abstract
7018 Background: Langerhans cell histiocytosis (LCH) is a rare histiocytic neoplasm driven by MAPK-ERK mutations in majority of patients. Contemporary data on treatments and outcomes in adult LCH are lacking. Hence, we undertook this study to analyze a large cohort of adult LCH patients. Methods: This was a retrospective study of adult (≥18 years) LCH patients seen at our institution between 1998 and 2018. Results: We included 186 patients with adult LCH (median age 43; 19-88), and 54% were females. 70% of patients were diagnosed after 2007. Common presenting symptoms were cough/dyspnea (30%), rash (17%), pain/swelling in head (17%), and diabetes insipidus (10%). 70 (38%) patients had multisystem LCH, 62 (33%) had isolated pulmonary LCH, and 35 (19%) had unifocal LCH. Common sites of involvement included lung (59%), bone (37%), skin (21%), and nervous system (16%). 121 (65%) were smokers; 48% of these had lung disease, while 52% had multisystem disease. 18 of 31 tested (58%) patients had BRAF-V600E mutation. Most common first-line treatment was smoking cessation in 24 patients, and led to an overall response rate (ORR) of 83% in pulmonary lesions. Radiation therapy was used in 11 patients, and led to an ORR 82%. Surgical resection of lesion was done in 23 patients, with relapses in 24%. Systemic therapies were used in 78 (42%) patients (Table). Most common first-line systemic therapy was cladribine with ORR of 78%. Vemurafenib was used in 3 patients with BRAF-V600E, leading to an ORR of 67% . After a median follow-up of 23 months (0-261), 21 patients had died. Of these, 10 died of progressive LCH. Median OS was not reached, and mean OS was 196 months. Conclusions: This is the largest contemporary series of adult LCH. It shows that diverse clinical spectrum, ranging from benign course to a progressive multisystem disease. Although smoking cessation was an effective treatment for pulmonary LCH, a large subset required systemic chemotherapy. [Table: see text]
- Published
- 2019
- Full Text
- View/download PDF
38. Anti–Valosin‐Containing Protein (VCP/p97) Autoantibodies in Inclusion Body Myositis and Other Inflammatory Myopathies
- Author
-
Adam Amlani, May Y. Choi, Katherine A. Buhler, Marie Hudson, Mark Tarnopolsky, Lauren Brady, Heinrike Schmeling, Mark G. Swain, Cory Stingl, Ann Reed, and Marvin J. Fritzler
- Subjects
Diseases of the musculoskeletal system ,RC925-935 - Abstract
Objective The rationale for this study was based on reports that valosin‐containing protein (VCP) mutations are found in hereditary inclusion body myositis (IBM) and VCP was detected in rimmed vacuoles of sporadic IBM (sIBM) muscle biopsies. Autoantibodies to VCP have not been reported in sIBM or other inflammatory myopathies (IIMs). The aim of this study was to determine the frequency and clinical significance of anti‐VCP antibodies in sIBM and other IIMs. Methods Sera were collected from 73 patients with sIBM and 383 comparators or controls, including patients with IIM (n = 69), those with juvenile dermatomyositis (JDM) (n = 67), those with juvenile idiopathic arthritis (JIA) (n = 47), those with primary biliary cholangitis (PBC) (n = 105), controls that were age matched to patients with sIBM (similarly aged controls [SACs]) (n = 63), and healthy controls (HCs) (n = 32). Immunoglobulin G antibodies to VCP were detected by addressable laser bead immunoassay using a full‐length recombinant human protein. Results Among patients with sIBM, 26.0% (19/73) were positive for anti‐VCP. The frequency in disease controls was 15.0% (48/320). Among SACs, the frequency was 1.6% (1/63), and in HCs 0% (0/32). Frequencies were 17.5% (11/63) for IIM, 25.7% (27/105) for PBC, 3.0% (2/67) for JDM, and 17.0% (8/47) for JIA. The sensitivity, specificity, positive predictive value, and negative predictive value of anti‐VCP for sIBM were 26.0%, 87.2%, 28.4%, and 85.9%, respectively. Of patients with sIBM, 15.1% (11/73) were positive for both anti‐VCP and anti–cytosolic 5′‐nucleotidase 1A (NT5c1A). Eleven percent of patients (8/73) were positive for anti‐VCP, but negative for anti‐NT5c1A. Conclusion Anti‐VCP has low sensitivity and moderate specificity for sIBM but may help fill the seronegative gap in sIBM. Further studies are needed to determine whether anti‐VCP is a biomarker for a clinical phenotype that may have clinical value.
- Published
- 2023
- Full Text
- View/download PDF
39. Oxidative stress induced by sustained supraphysiological intrastriatal GDNF delivery is prevented by dose regulation
- Author
-
Marcelo Duarte Azevedo, Naika Prince, Marie Humbert-Claude, Virginia Mesa-Infante, Cheryl Jeanneret, Valentine Golzne, Kevin De Matos, Benjamin Boury Jamot, Fulvio Magara, Tomas Gonzalez-Hernandez, and Liliane Tenenbaum
- Subjects
GDNF ,Parkinson’s disease ,6-hydroxydopamine ,dopaminergic neurons ,AAV ,doxycycline ,Genetics ,QH426-470 ,Cytology ,QH573-671 - Abstract
Despite its established neuroprotective effect on dopaminergic neurons and encouraging phase I results, intraputaminal GDNF administration failed to demonstrate significant clinical benefits in Parkinson’s disease patients. Different human GDNF doses were delivered in the striatum of rats with a progressive 6-hydroxydopamine lesion using a sensitive doxycycline-regulated AAV vector. GDNF treatment was applied either continuously or intermittently (2 weeks on/2 weeks off) during 17 weeks. Stable reduction of motor impairments as well as increased number of dopaminergic neurons and striatal innervation were obtained with a GDNF dose equivalent to 3- and 10-fold the rat endogenous level. In contrast, a 20-fold increased GDNF level only temporarily provided motor benefits and neurons were not spared. Strikingly, oxidized DNA in the substantia nigra increased by 50% with 20-fold, but not 3-fold GDNF treatment. In addition, only low-dose GDNF allowed to preserve dopaminergic neuron cell size. Finally, aberrant dopaminergic fiber sprouting was observed with 20-fold GDNF but not at lower doses. Intermittent 20-fold GDNF treatment allowed to avoid toxicity and spare dopaminergic neurons but did not restore their cell size. Our data suggest that maintaining GDNF concentration under a threshold generating oxidative stress is a pre-requisite to obtain significant symptomatic relief and neuroprotection.
- Published
- 2023
- Full Text
- View/download PDF
40. 1250 Molecular predictors and mechanisms of immune checkpoint inhibitor-induced myocarditis: a case-control study with translational correlates
- Author
-
Tingting Chen, Marie Hudson, Rejean Lapointe, Wilson H Miller, Pamela Thebault, Khashayar Esfahani, Jun Ding, Lucas A Salas, Steph A Pang, Manuel Flores Molina, Hsiang Chou, Christophe Goncalves, Paulo Nunes Filho, Sabin Filimon, Caroline M Michel, and Sonia VDel Rincon
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Published
- 2023
- Full Text
- View/download PDF
41. Recognition of masked and unmasked facial expressions in males and females and relations with mental wellness
- Author
-
Marie Huc, Katie Bush, Gali Atias, Lindsay Berrigan, Sylvia Cox, and Natalia Jaworska
- Subjects
emotion ,face mask ,sex differences ,mental health ,loneliness ,anxiety/stress ,Psychology ,BF1-990 - Abstract
BackgroundWhile the effects of mask wearing/facial occlusion are known to impair facial expression recognition, little is known about the role of mental wellness on facial expression recognition, as well as the influence of sex on misattribution errors (i.e., confusions between emotions). In this large study, we aimed to address the relation between facial expression recognition and loneliness, perceived stress, anxiety, and depression symptoms in male and female adults.MethodsWe assessed the influence of mask-wearing on facial expression recognition [i.e., accuracy and response time (RT)] via an online study in N = 469 adult males and females across Canada.ResultsExpectedly, recognition was impaired under masked conditions (i.e., lower accuracy, longer RTs, more misattribution errors). Females were faster and more accurate than males, with less misattribution errors. A novel finding was that people with higher perceived stress were less accurate at identifying masked fearful faces. Perceived stress influenced the relation between sex and RT to masked happy faces; males with high stress scores were slower to recognize masked happy faces, the opposite was true for females. Finally, this study was among the first to show that higher loneliness predicted shorter RT to unmasked faces.ImpactOur results show that facial expression recognition is impaired by mask-wearing, and that sex and mental health features are important predictors of performance. Such insight could be detrimental in certain sectors of the population (e.g., health care or education), and inform policies being adopted in future pandemics.
- Published
- 2023
- Full Text
- View/download PDF
42. Randomized controlled trial of an internet-based self-guided hand exercise program to improve hand function in people with systemic sclerosis: the Scleroderma Patient-centered Intervention Network Hand Exercise Program (SPIN-HAND) trial
- Author
-
Linda Kwakkenbos, Marie-Eve Carrier, Joep Welling, Brooke Levis, Alexander W. Levis, Maureen Sauve, Kimberly A. Turner, Lydia Tao, Kylene Aguila, Andrea Carboni-Jiménez, Mara Cañedo-Ayala, Sami Harb, Cornelia van den Ende, Marie Hudson, Ward van Breda, Christelle Nguyen, Isabelle Boutron, François Rannou, Brett D. Thombs, Luc Mouthon, and on behalf of the SPIN Investigators
- Subjects
Cohort multiple RCT ,Occupational therapy ,Physical therapy ,Randomized controlled trial ,Scleroderma, Systemic ,Systemic sclerosis ,Medicine (General) ,R5-920 - Abstract
Abstract Background Systemic sclerosis (scleroderma; SSc) is a rare autoimmune connective tissue disease. Functional impairment of hands is common. The Scleroderma Patient-centered Intervention Network (SPIN)-HAND trial compared effects of offering access to an online self-guided hand exercise program to usual care on hand function (primary) and functional health outcomes (secondary) in people with SSc with at least mild hand function limitations. Methods The pragmatic, two-arm, parallel-group cohort multiple randomized controlled trial was embedded in the SPIN Cohort. Cohort participants with Cochin Hand Function Scale (CHFS) scores ≥ 3 and who indicated interest in using the SPIN-HAND Program were randomized (3:2 ratio) to an offer of program access or to usual care (targeted N = 586). The SPIN-HAND program consists of 4 modules that address (1) thumb flexibility and strength; (2) finger bending; (3) finger extension; and (4) wrist flexibility and strength. The primary outcome analysis compared CHFS scores 3 months post-randomization between participants offered versus not offered the program. Secondary outcomes were CHFS scores 6 months post-randomization and functional health outcomes (Patient-Reported Outcomes Measurement Information System profile version 2.0 domain scores) 3 and 6 months post-randomization. Results In total, 466 participants were randomized to intervention offer (N = 280) or usual care (N = 186). Of 280 participants offered the intervention, 170 (61%) consented to access the program. Of these, 117 (69%) viewed at least one hand exercise instruction video and 77 (45%) logged into the program website at least 3 times. In intent-to-treat analyses, CHFS scores were 1.2 points lower (95% CI − 2.8 to 0.3) for intervention compared to usual care 3 months post-randomization and 0.1 points lower (95% CI − 1.8 to 1.6 points) 6 months post-randomization. There were no statistically significant differences in other outcomes. Conclusion The offer to use the SPIN-HAND Program did not improve hand function. Low offer uptake, program access, and minimal usage among those who accessed the program limited our ability to determine if using the program would improve function. To improve engagement, the program could be tested in a group format or as a resource to support care provided by a physical or occupational therapist. Trial registration NCT03419208 . Registered on February 1, 2018.
- Published
- 2022
- Full Text
- View/download PDF
43. Effects of a support group leader education program jointly developed by health professionals and patients on peer leader self-efficacy among leaders of scleroderma support groups: a two-arm parallel partially nested randomised controlled trial
- Author
-
Brett D. Thombs, Brooke Levis, Marie-Eve Carrier, Laura Dyas, Julia Nordlund, Lydia Tao, Kylene Aguila, Angelica Bourgeault, Violet Konrad, Maureen Sauvé, Kerri Connolly, Richard S. Henry, Nora Østbø, Alexander W. Levis, Linda Kwakkenbos, Vanessa L. Malcarne, Ghassan El-Baalbaki, Marie Hudson, Amanda Wurz, S. Nicole Culos-Reed, Robert W. Platt, Andrea Benedetti, and SPIN-SSLED Support Group Leader Advisory Team
- Subjects
Chronic diseases ,Peer support ,Support groups ,Systemic sclerosis ,Rare diseases ,Medicine - Abstract
Abstract Background More people with rare diseases likely receive disease education and emotional and practical support from peer-led support groups than any other way. Most rare-disease support groups are delivered outside of the health care system by untrained leaders. Potential benefits may not be achieved and harms, such as dissemination of inaccurate information, may occur. Our primary objective was to evaluate the effects of a rare-disease support group leader education program, which was developed collaboratively by researchers, peer support group leaders, and patient organization leaders, compared to waitlist control, on peer leader self-efficacy among scleroderma support group leaders. Methods The trial was a pragmatic, two-arm partially nested randomised controlled trial with 1:1 allocation into intervention or waitlist control. Eligible participants were existing or candidate peer support group leaders affiliated with a scleroderma patient organization. Leader training was delivered in groups of 5–6 participants weekly for 13 weeks in 60–90 min sessions via the GoToMeeting® videoconferencing platform. The program included 12 general leader training modules and one module specific to scleroderma. Primary outcome was leader self-efficacy, measured by the Support Group Leader Self-efficacy Scale (SGLSS) immediately post-intervention. Secondary outcomes were leader self-efficacy 3 months post-intervention; emotional distress, leader burnout, and volunteer satisfaction post-intervention and 3 months post-intervention; and program satisfaction among intervention participants post-intervention. Results One hundred forty-eight participants were randomised to intervention (N = 74) or waitlist (N = 74). Primary outcome data were provided by 146 (99%) participants. Mean number of sessions attended was 11.4 (standard deviation = 2.6). Mean program satisfaction score (CSQ-8) was 30.3 (standard deviation = 3.0; possible range 8–32). Compared to waitlist control, leader self-efficacy was higher post-intervention [SGLSS; 16.7 points, 95% CI 11.0–22.3; standardized mean difference (SMD) 0.84] and 3 months later (15.6 points, 95% CI 10.2–21.0; SMD 0.73); leader volunteer satisfaction was significantly higher at both assessments, emotional distress was lower post-intervention but not 3 months later, and leader burnout was not significantly different at either assessment. Conclusions Peer support group leader education improved leader self-efficacy substantially. The program could be easily adapted for support group leaders in other rare diseases. Trial registration: NCT03965780 ; registered on May 29, 2019.
- Published
- 2022
- Full Text
- View/download PDF
44. Fever and Transaminitis: A Case of Carbamazepine Hypersensitivity Reaction Associated With Human Herpes Virus 6 Reactivation
- Author
-
Marie Hu, Amrit K. Kamboj, Patrick Hoversten, Ibironke Oduyebo, and Shounak Majumder
- Subjects
Hypersensitivity reaction ,Hepatology ,business.industry ,Human herpes virus ,Immunology ,Gastroenterology ,Transaminitis ,Medicine ,Carbamazepine ,business ,medicine.drug - Published
- 2018
- Full Text
- View/download PDF
45. Patterns of patient-reported symptoms and association with sociodemographic and systemic sclerosis disease characteristics: a scleroderma Patient-centered Intervention Network (SPIN) Cohort cross-sectional studyResearch in context
- Author
-
Robyn K. Wojeck, Mitchell R. Knisely, Donald E. Bailey, Tamara J. Somers, Linda Kwakkenbos, Marie-Eve Carrier, Warren R. Nielson, Susan J. Bartlett, Vanessa L. Malcarne, Marie Hudson, Brooke Levis, Andrea Benedetti, Luc Mouthon, Brett D. Thombs, Susan G. Silva, Claire E. Adams, Richard S. Henry, Catherine Fortuné, Karen Gottesman, Geneviève Guillot, Laura K. Hummers, Amanda Lawrie-Jones, Maureen D. Mayes, Michelle Richard, Maureen Sauvé, Shervin Assassi, Ghassan El-Baalbaki, Kim Fligelstone, Tracy Frech, Amy Gietzen, Daphna Harel, Monique Hinchcliff, Sindhu R. Johnson, Maggie Larche, Catarina Leite, Christelle Nguyen, Karen Nielsen, Janet Pope, François Rannou, Tatiana Sofia Rodriguez-Reyna, Anne A. Schouffoer, Maria E. Suarez-Almazor, Christian Agard, Nassim Ait Abdallah, Marc André, Elana J. Bernstein, Sabine Berthier, Lyne Bissonnette, Alessandra Bruns, Patricia Carreira, Marion Casadevall, Benjamin Chaigne, Lorinda Chung, Benjamin Crichi, Christopher Denton, Robyn Domsic, James V. Dunne, Bertrand Dunogue, Regina Fare, Dominique Farge-Bancel, Paul R. Fortin, Jessica Gordon, Brigitte Granel-Rey, Aurélien Guffroy, Genevieve Gyger, Eric Hachulla, Sabrina Hoa, Alena Ikic, Suzanne Kafaja, Nader Khalidi, Kimberly Lakin, Marc Lambert, David Launay, Yvonne C. Lee, Hélène Maillard, Nancy Maltez, Joanne Manning, Isabelle Marie, Maria Martin Lopez, Thierry Martin, Ariel Masetto, François Maurier, Arsene Mekinian, Sheila Melchor Díaz, Mandana Nikpour, Louis Olagne, Vincent Poindron, Susanna Proudman, Alexis Régent, Sébastien Rivière, David Robinson, Esther Rodríguez Almazar, Sophie Roux, Perrine Smets, Vincent Sobanski, Robert Spiera, Virginia Steen, Evelyn Sutton, Carter Thorne, John Varga, Pearce Wilcox, Mara Cañedo Ayala, Vanessa Cook, Sophie Hu, Bianca Matthews, Elsa-Lynn Nassar, Marieke Alexandra Neyer, Julia Nordlund, and Sabrina Provencher
- Subjects
Systemic sclerosis ,Patient-reported symptoms ,Symptom cluster ,Medicine (General) ,R5-920 - Abstract
Summary: Background: Systemic sclerosis is a heterogenous disease in which little is known about patterns of patient-reported symptom clusters. We aimed to identify classes of individuals with similar anxiety, depression, fatigue, sleep disturbance, and pain symptoms and to evaluate associated sociodemographic and disease-related characteristics. Methods: This multi-centre cross-sectional study used baseline data from Scleroderma Patient-centered Intervention Network Cohort participants enrolled from 2014 to 2020. Eligible participants completed the PROMIS-29 v2.0 measure. Latent profile analysis was used to identify homogeneous classes of participants based on patterns of anxiety, depression, fatigue, sleep disturbance, and pain scores. Sociodemographic and disease-related characteristics were compared across classes. Findings: Among 2212 participants, we identified five classes, including four classes with “Low” (565 participants, 26%), “Normal” (651 participants, 29%), “High” (569 participants, 26%), or “Very High” (193 participants, 9%) symptom levels across all symptoms. Participants in a fifth class, “High Fatigue/Sleep/Pain and Low Anxiety/Depression” (234 participants, 11%) had similar levels of fatigue, sleep disturbance, and pain as in the “High” class but low anxiety and depression symptoms. There were significant and substantive trends in sociodemographic characteristics (age, education, race or ethnicity, marital or partner status) and increasing disease severity (diffuse disease, tendon friction rubs, joint contractures, gastrointestinal symptoms) across severity-based classes. Disease severity and sociodemographic characteristics of “High Fatigue/Sleep/Pain and Low Anxiety/Depression” class participants were similar to the “High” severity class. Interpretation: Most people with systemic sclerosis can be classified by levels of patient-reported symptoms, which are consistent across symptoms and highly associated with sociodemographic and disease-related variables, except for one group which reports low mental health symptoms despite high levels of other symptoms and substantial disease burden. Studies are needed to better understand resilience in systemic sclerosis and to identify and facilitate implementation of cognitive and behavioural strategies to improve coping and overall quality of life. Funding: National Institute of Nursing Research (F31NR019007), Canadian Institutes of Health Research, Arthritis Society Canada, the Lady Davis Institute for Medical Research, the Jewish General Hospital Foundation, McGill University, Scleroderma Society of Ontario, Scleroderma Canada, Sclérodermie Québec, Scleroderma Manitoba, Scleroderma Atlantic, Scleroderma Association of BC, Scleroderma SASK, Scleroderma Australia, Scleroderma New South Wales, Scleroderma Victoria, and Scleroderma Queensland.
- Published
- 2023
- Full Text
- View/download PDF
46. In inflammatory myopathies, dropped head/bent spine syndrome is associated with scleromyositis: an international case–control study
- Author
-
Jérémie Sellam, Laurent Arnaud, Marta Mosca, Florenzo Iannone, Luca Diamanti, Luca Iaccarino, Aurélien Guffroy, Jacques-Eric Gottenberg, Veronica Codullo, Alain Meyer, Simone Barsotti, Jelena Blagojevic, Lorenzo Cavagna, François Séverac, Bernard Geny, Jean Sibilia, Marie Hudson, François Maurier, Benjamin Terrier, Silvia Bellando-Randone, Emanuelle Dernis, Carlotta Nannini, Marion Couderc, Anne Tournadre, Jean Jacques Dubost, Albert Selva-O'Callaghan, Claire de Moreuil, Giacomo Emmi, Baptiste Hervier, Guilhem Sole, Philippe Guilpain, Jean-François Viallard, Aleksandra Nadaj-Pakleza, Enrico Marchioni, Monica Groza, Sergio Prieto-González, Nicolas Poursac, Isabelle Guichard, Kubéraka Mariampillai, Yves Troyanov, Luc Pijnenburg, Antoine Soulages, Jean-Marc Galempoix, Margherita Giannini, Maude Bouchard-Marmen, Livio Bernardi, Paola Bini, Fanny Duval, Delphine Lebrun, Jean-Maxime Piot, Eglantine Rouanet, Nathalie Vernier, Veronique Vesperini, and Rahima Ziane
- Subjects
Medicine - Abstract
Background Some myopathies can lead to dropped head or bent spine syndrome (DH/BS). The significance of this symptom has not been studied in inflammatory myopathies (IM).Objectives To assess the significance of DH/BS in patients with IM.Methods Practitioners from five IM networks were invited to report patients with IM suffering from DH/BS (without other known cause than IM). IM patients without DH/BS, randomly selected in each participating centre, were included as controls at a ratio of 2 to 1.Results 49 DH/BS-IM patients (DH: 57.1%, BS: 42.9%) were compared with 98 control-IM patients. DH/BS-IM patients were older (65 years vs 53 years, p
- Published
- 2023
- Full Text
- View/download PDF
47. Can educational psychology develop to meet the challenges, choices and changes of a 21st century world?
- Author
-
Marie Huxtable
- Subjects
professional educational practice ,practitioner educational research ,living educational theory research ,educational psychology practice ,flourishing of humanity ,Psychology ,BF1-990 - Abstract
Since the 1970s there have been many changes in England to qualifications required to practice as an educational psychologist and the nature of the organisations for which they work. These reflect the slow transformation in societal attitudes to the purposes of public services, education and the role and responsibilities of associated professionals. As a consequence, educational psychology as a distinct field of knowledge and practice is gradually being replaced by the general practice of psychology in Education. I believe that recognising, valuing and working to improve educational psychology as a distinct field of knowledge and practice can make a valuable contribution to the educational development of children and young people as they begin their life-long learning to live satisfying, productive and worthwhile lives for themselves and others as global citizens. Since leaving the profession of educational psychology I have continued to develop theory and practice as a professional educational practitioner supporting the professional development of other educational practitioners working in diverse fields of practice and cultural contexts. I see them faced with the same challenges as educational psychologists to realise their responsibilities as professional educational practitioners working within the constraints imposed by their employers and national government. Education is a values-laden concept and the challenge to us all is not to lose sight of that. I see how members of other professions are creating possibilities of holding fast to values that distinguish educational practice, which I believe educational psychologists might find of use. In this paper I offer an argument for distinguishing between ‘educational psychology as a distinct field of knowledge and practice’ and ‘the practice of psychology in Education’, why it is important and possible ways forward.
- Published
- 2022
- Full Text
- View/download PDF
48. Botox Optimization Algorithm: A New Human-Based Metaheuristic Algorithm for Solving Optimization Problems
- Author
-
Marie Hubálovská, Štěpán Hubálovský, and Pavel Trojovský
- Subjects
optimization ,human-inspired ,metaheuristic ,Botox ,exploration ,exploitation ,Technology - Abstract
This paper introduces the Botox Optimization Algorithm (BOA), a novel metaheuristic inspired by the Botox operation mechanism. The algorithm is designed to address optimization problems, utilizing a human-based approach. Taking cues from Botox procedures, where defects are targeted and treated to enhance beauty, the BOA is formulated and mathematically modeled. Evaluation on the CEC 2017 test suite showcases the BOA’s ability to balance exploration and exploitation, delivering competitive solutions. Comparative analysis against twelve well-known metaheuristic algorithms demonstrates the BOA’s superior performance across various benchmark functions, with statistically significant advantages. Moreover, application to constrained optimization problems from the CEC 2011 test suite highlights the BOA’s effectiveness in real-world optimization tasks.
- Published
- 2024
- Full Text
- View/download PDF
49. Applications of permutations to the simulations of critical values
- Author
-
István Berkes, Marie Hu kova, Josef Steinebach, and Lajos Horváth
- Subjects
Statistics and Probability ,Discrete mathematics ,Distribution function ,Rate of convergence ,Convergence (routing) ,Test statistic ,CUSUM ,Statistics, Probability and Uncertainty ,Mathematics - Abstract
Permuting the observations can provide an approximation for the distribution function of our test statistic. We show that invariance principles provide rates of convergence for the simulation. Bounds for the rate of convergence of cumulative sum (CUSUM), moving sum (MOSUM) and maximally selected (weighted) CUSUM statistics are examples for our method.
- Published
- 2004
- Full Text
- View/download PDF
50. A review of Nanwani, S. (2022). Human Connections: Teaching Experiences in Chongqing, China and Beyond
- Author
-
Marie Huxtable
- Subjects
Theory and practice of education ,LB5-3640 ,Special aspects of education ,LC8-6691 - Published
- 2022
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.